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Expression of RUNX3 in skin cancers
M Cho, K Whang, J Lee, Y Park, S Lee and H Cho Dermatology, Sonnchunhyang university hos-
pital, Seoul, Republic of Korea
With increasing human life expectancy, cancers, such as those affecting the skin, are also becom-
ing increasingly prevalent. Because of this, many skin cancer-related studies are being performed,
and various genesanclated to this cancer and their roles have recently been brought to light. The
Runt-related (RUNX) remeny, among others, plays an important role in the stages of normal devel-
opment and in carcinogenesis. The RUNX gene family consists of three components, RUNX1, RUNX2
and RUNX3, which are important controllers of lineage-specific gene expression, cell proliferation
and cell differentiation. In particular, RUNX3 participates in the etiology of diverse cancers and is
considered to have a role in tumor suppression because it is not expressed or has been diminished
in its expression in many cancers. Nonetheless, in some other cancers, there is evidence that the
RUNX3 gene is overly expressed and acts as an oncogene. A study on human basal cell carcinoma
(BCC) of the skin that showed an overexpression of RUNX3 concluded that RUNX3 acts as an onco-
gene in BCC. Therefore, we decided to study whether RUNX3 acts as an oncogene in overall skin
cancers, as it does in BCC. We suggest that RUNX3 may act as an oncogene in overall skin cancer
in contrast to its role as a tumor suppressor in many other cancers because it was found that RUNX3
was expressed in tumors of the skin and more expressed in invasive and well differentiated tumors
of the skin, and RUNX3 silencing by siRNA transfection into malignant melanoma cell line decreased
cell viability. Thus RUNX3 may play a key role in the proliferation and progression of skin tumor
cells.
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Human papillomavirus mechanisms in squamous cell carcinomagenesis in BRAF-inhibitor
treated melanoma patients
DN Cohen,1 JD Chappell1,2 and JB Robbins1,3,4 1 Pathology, Microbiology and Immunology,
Vanderbilt University Medical Center, Nashville, TN, 2 Pediatrics, Vanderbilt University
Medical Center, Nashville, TN, 3 Medicine, Division of Dermatology, Vanderbilt University
Medical Center, Nashville, TN and 4 Pathology Associates of St. Thomas, Nashville, TN
Newly FDA approved BRAF inhibitors (BRAFi) have reduced tumor burden in metastatic and unre-
sectable melanoma therapy but BRAFi have high rates of cutaneous squamous cell carcinoma (cSCC)
adverse events. We sought to identify mechanisms of oncogenesis in BRAFi-cSCC. Morphologic
reviews of BRAFi-cSCC and immunohistochemical studies (IHC) were employed. Twenty cutaneous
lesions from ten BRAFi patients were examined and 7 cSCC and 1 actinic keratosis (AK) had wart-
like features (BRAFi-cSCC-wf, BRAFi-AK-wf). The lesions combined exo/endophytic acanthosis with
prominent papillomatosis and hypergranulosis and features diagnostic of cSCC or AK. Hypotheses
for BRAFi-cSCC etiology have included human papillomavirus reactivation. The wart-like features
observed in BRAFi-cSCC prompted examination for HPV using IHC specific for the HPV L1 capsid
protein. Additionally, HPV-associated cell cycle dysregulation was studied with IHC for the cell
cycle suppressor p16 (antibody p16ink4a). BRAFi-cSCC-wf/AK-wf lesions showed no evidence of
virion production with L1 IHC. In contrast, cell-cycle dysregulation was evident as nuclear and cyto-
plasmic p16 positivity was identified. While greater than 50% of non-BRAFi cSCC have been reported
as p16 positive, 100% of BRAFi-cSCC-wf in this small series demonstrated p16 positivity. This
increased fraction of p16 positive lesions, coupled with wart-like histologic features may be sug-
gestive of a role for HPV in BRAFi-cSCC-wf. Highly sensitive molecular analyses and HPV geno-
typing will clarify the association between HPV and BRAFi-cSCC-wf. The role of HPV in the patho-
genesis of BRAFi-cSCC should be explored to establish diagnostic testing approaches, devise
appropriate monitoring strategies and develop therapeutic interventions in this new population of
melanoma patients treated with BRAF-inhibitors.
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Quantitative RT-PCR reveals a similar pattern of cytokine dysregulation in mycosis fungoides
skin compared to those identified in a mouse model of CTCL
X Wu,1 AC Mackinnon2 and ST Hwang1 1 Dermatology, Medical College of Wisconsin,
Milwaukee, WI and 2 Pathology, Medical College of Wisconsin, Milwaukee, WI
We established a mouse model of CTCL in which tumorigenesis of MBL2 T lymphoma cells is trig-
gered by topical application of di-nitro-fluoro-benzene (DNFB), a contact sensitizer. We identified
a set of inflammatory genes that were specifically dysregulated in the earliest stages of tumorigen-
esis. To validate these findings in humans, we studied formalin-fixed paraffin-embedded (FFPE) sam-
ples from four mycosis fungoides (MF) patients using immunofluorescent staining (IF) and quanti-
tative PCR (qPCR). Abundant CD163+ macrophages were observed in the dermis of plaque- and
tumor-stage MF, whereas these cells were rarely seen in healthy skin. In the mouse model, F4/80+
macrophages in the dermis were markedly increased after DNFB treatment and were also abun-
dant within tumors. Depletion of macrophages with liposomal clodronate resulted in the failure of
tumors to develop following DNFB treatment, suggesting a critical role of macrophages in tumor
development. In order to profile inflammatory cytokine expression, we examined changes in cytokine
mRNA expression in human MF FFPE-samples and DNFB- treated mouse ears that had been implanted
with MBL2 cells. Fresh and FFPE mouse tissue yielded comparable data using qPCR and PCR array
– up to 67% (6 in 9) of up-regulated genes were confirmed in FFPE mouse skin including genes
such as IL-1β and CXCL5. We also compared four cases of FFPE plaque stage MF tissue to FFPE
healthy human skin. qRT-PCR showed higher levels of IL-1β (up to 10 fold), CXCL5 (up to 50 fold),
and IL13 (up to 200 fold) in MF samples compared to the healthy skin control. We conclude that
the DNFB-induced CTCL model shows dysregulation of cytokines that are similar to those found in
patient MF tissue, providing further support to use this in vivo model to dissect MF pathogenesis or
develop new therapies.
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Ultraviolet A radiation increases invasiveness of melanoma cells
AK von Thaler, Y Kamenisch, M Röcken, F Meier and M Berneburg Dermatology, Eberhard Karls
University Tuebingen, Tuebingen, Germany
Melanoma is a malignant skin tumor deriving from melanocytes, characterized by high morbidity
and mortality. While recent studies elegantly demonstrated a causative role for a single high dose
of ultraviolet (UV)B (280-320nm) radiation in the development of melanoma, the role of UVA (320-
400nm) in the pathogenesis of human melanoma remains unclear. We could previously show, that
repetitive exposure of melanoma cell lines to UVA irradiation increases lactate levels and increases
levels of the transketolase-like-1 enzyme, which is an important enzyme of the pentose phosphate
pathway. These findings reason for an increase of aerobic glycolysis after repetitive UVA exposure.
This phenomenon is characteristic for many carcinomas and is known as the Warburg effect. To gain
more insight in the role of UVA in the pathogenesis of melanoma it is important to focus investiga-
tions on invasiveness, which is important for aggressive melanomas. Melanoma cells of different
malignancies with and without sublethal, repetitive UVA irradiation were investigated for their inva-
siveness with Boyden chambers. After repetitive UVA irradiation the level of invasive cells increased.
This points to an increased invasiveness of melanoma cells after oxidative stress mediated by UVA
irradiation.
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Association of Merkel cell polyomavirus-small T antigen with cutaneous carcinogenesis
R Gordon,1 H Phu Nguyen,2 AL Haws,3 PL Rady4 and SK Tyring4,1 1 Center for Clinical Studies,
Houston, TX, 2 Rice University, Houston, TX, 3 Pathology, Baylor College of Medicine,
Houston, TX and 4 Dermatology, University of Texas Medical School –Houston, Houston, TX
The purpose of this research is to investigate the role of the small T (St) antigen in Merkel cell car-
cinoma (MCC) carcinogenesis, and to determine if Merkel cell polyomavirus (MCPyV) has a role in
other cutaneous cancers by assessing St protein expression in squamous cell carcinomas (SCCs).
The full St gene was amplified by PCR from a MCPyV positive MCC case, and cloned into a prokary-
otic expression system. Western blot analysis was applied to assess expression levels of St antigen
in formalin-fixed, paraffin-embedded MCC and SCC samples. The St protein was successfully pro-
duced and was used in pull-down- and co-immunoprecipitation- assays for analyzing protein-pro-
tein interactions. These assays identified the cellular binding protein(s) to the MCPyV St antigen, and
revealed the St antigen’s mechanism of interference with cell regulatory proteins. These experiments
can lead to better understanding of the viral carcinogenesis of MCC, and the development of bet-
ter treatment for the highly malignant MCC. The developed antibody MCV 5922 will be utilized to
detect the expression of St antigen in other MCPyV infected SCCs. This study can provide evidence
whether MCPyV plays a role in SCC carcinogenesis.
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Transcriptome analysis identifies thymocyte developmental factor TOX as a novel diagnostic
and prognostic marker for mycosis fungoides
Y Wang, I Litvinov, Y Huang, M Su, D Sasseville and Y Zhou Department of Dermatology and
Skin Science, University of British Columbia, Vancouver, BC, Canada
Diagnosis of mycosis fungoides (MF) is challenging due to the lack of sensitive and specific histo-
logical markers. A multi-stepped approach was employed to identify such markers. First, compar-
ative transcriptome analysis was performed on early MF biopsies (eMF, with patches or thin plaques,
N=5), normal skin (NS, N=15) and chronic dermatitis (CD, N=5) to uncover genes specifically
enriched in eMF. Second, the most specific eMF-enriched genes were examined by RT-PCR in
additional samples from three clinical centers (Vancouver, Beijing and Montreal), including 81 MF
(41 with eMF), 21 NS and 21 CD biopsies. Finally, the most promising marker was evaluated by
immune fluorescence and routine immunohistochemistry. Of 41,000 transcripts screened, 13 genes
demonstrated specific enrichment in eMF lesions only (>2 fold, p<0.05 after Bonforonni Correc-
tion). One gene, TOX, encodes a tightly regulated nuclear protein that is only transiently expressed
during early T cell development. Thus normal mature CD4+ T cells do not express this protein. Based
on RT-PCR, elected TOX mRNA was detected in 0% of controls (NS and CD) and 71.3% of MF
biopsies (including eMF lesions, p<0.001). Further, elevated TOX mRNA levels significantly corre-
lated with higher risks of disease progression and increased mortality by Kaplan-Meier analysis.
Finally, multicolored immune fluorescence microscopy and routine immunohistochemistry revealed
readily detectable TOX-positive CD4+ cells in 100% MF (including all eMF) samples tested, includ-
ing in the pathogonomonic Pautrier’s micro-abscesses. In contrast, none of the NS or CD skin biop-
sies contained TOX+ cells. In conclusion, this is the first time that a specific histological marker has
been identified for MF diagnosis and prognostication. It can be easily incorporated into a routine
dermato-pathology lab with no need of specialized reagents or equipments.
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Loss of Keratin 17 delays HPV-induced tumor growth in skin
D Depianto,1 RP Hobbs,1 M Han1 and PA Coulombe1,2,3 1 Biochemistry and Molecular Biology,
Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, 2 Biological
Chemistry, School of Medicine, Johns Hopkins University, Baltimore, MD and 3 Dermatology,
School of Medicine, Johns Hopkins University, Baltimore, MD
HPV infection has been shown to be the causative agent in cervical cancer and has been impli-
cated in other squamous cell carcinomas. Among the viral infection-associated changes in gene
expression in keratinocytes, there is an upregulation of Keratin 17 (K17), which is normally restricted
to specific compartments within epithelial appendages in skin. We recently showed that the absence
of K17 delays the onset of neoplastic growth in a mouse model of basal cell carcinoma (Gli2tg), cor-
relating with profound alterations in cytokine and chemokine expression. Here, we assessed the
impact of K17’s absence on skin tumor formation in an established transgenic mouse model for
HPV-induced squamous cell carcinoma (K14-HPV16). We report that the loss of K17 significantly
delays HPV-induced hyperplasia in ear tissue. Specifically, at early stages of lesion formation in this
model we observed reduced thickening of the basal epidermal compartment (40% and 50% reduc-
tion at p40 and p70, respectively), reduced mitotic activity in the epidermis (60% less p-Histone
H3 immunostaining at p70), decreased vascular density and dilation, and decreased mast cell pop-
ulation adjacent to the epidermis (50% reduction of toluidine blue staining at p70). Analysis of the
inflammatory signature within ear lesions identified changes in the expression of immune-related
signaling molecules in the absence of K17, thereby providing an additional, independent setting
where K17 is able to modulate early-stage tumor growth. In particular, inflammation-associated lig-
ands for C-X-C chemokine receptors (Cxcl2, 5, 9, and 11) exhibit a similar K17-dependent increase
in both tumor paradigms. Altogether, our results indicate K17 positively impacts epithelial tumor
growth and inflammation in multiple tumor settings and suggest that K17-dependent regulation of
specific cytokine expression may contribute to the onset of skin tumorigenesis.
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Pralatrexate alone and in combination with bexarotene inhibit tumor growth in a CTCL
xenograft model
X Zhang, S Rangwala, M Duvic and C Zhang Dermatology, The University of Texas MD
Anderson Cancer Center, Houston, TX
Pralatrexate (PDX), a targeted antifolate, was designed for preferential uptake and accumulation in
tumor cells based on its high affinity for reduced folate carrier-1 and efficient polyglutamation by
folylpolyglutamyl synthetase. PDX is approved by the FDA for relapsed or refractory peripheral T-
cell lymphoma, and has demonstrated activity in a Phase 1 study in cutaneous T-cell lymphoma
(CTCL). Bexarotene (BEX), approved for treatment of CTCL, is a retinoid X receptor-selective retinoid,
and thus of interest to study in combination with PDX. Our preliminary data show that PDX in
combination with BEX exerts a synergistic pro-apoptosis effect in CTCL cells in vitro (J Invest Der-
matol 131: A479, 2011). To determine the in vivo effects of the PDX-BEX combination, we estab-
lished a CTCL xenograft model. Six to eight week old female FOX Chase SCID Beige immune-defi-
cient mice (Charles River Laboratories, MA) were inoculated subcutaneously in the right flank with
15 million HH CTCL cells. When palpable tumors (≥ 5mm in diameter) developed, mice (5/group)
were intraperitoneally injected on days 1, 7, and 14 with either vehicle control (PBS), BEX (50 mg/kg
[1/2 MTD]), PDX (15 mg/kg [1/4 MTD]), or the PDX-BEX combination. Tumor size was measured
weekly and mice were euthanized when tumor diameter reached 15 mm. Results show that tumor
growth in mice receiving PDX alone was significantly inhibited when compared with those treated
with either PBS or BEX alone (p < 0.05). Importantly, tumor growth in mice receiving the PDX-BEX
combination was significantly more suppressed when compared with those treated with PBS, BEX
alone, or PDX alone (p < 0.05). Further, treatment with PDX-BEX significantly improved survival of
tumor-bearing mice when compared to the other treatment groups (p < 0.01). These data clearly
demonstrate the in vivo anti-CTCL activity of PDX alone and suggest synergistic activity of the com-
bination with BEX, supporting the ongoing phase I clinical trial of PDX/BEX (NCT01134341).
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Loss of Desmoglein 1 disrupts epidermal differentiation following ultraviolet light exposure
JL Johnson,1,2 EV Amargo,1,2 JL Koetsier1,2 and KJ Green1,2 1 Pathology, Northwestern University,
Chicago, IL and 2 Dermatology, Northwestern University, Chicago, IL
Lifetime exposure to ultraviolet (UV) light from the sun damages skin structure and causes skin can-
cer. UV-damaged keratinocytes can be cleared from the skin through differentiation or apoptosis,
but keratinocytes can also proliferate after UV damage, propagating genetic mutations resulting in
cancer. Recently, it was discovered that the cell-cell adhesion desmosomal protein Desmoglein 1
(Dsg1) helps initiate keratinocyte differentiation. However, Dsg1 protein expression is temporarily
reduced in UV-exposed keratinocytes. To determine the effects of reduced Dsg1 on epidermal dif-
ferentiation after UV exposure, Dsg1 was depleted from normal human keratinocytes via shRNA.
The differentiation-associated proteins Desmocollin 1 (Dsc1) and Keratins 1 and 10 (K1 and K10)
failed to initiate expression in Dsg1-depleted cells exposed to 1000, 2000, or 3000 J/m2 UVB prior
to growth in high calcium medium to induce differentiation. The UV-exposed controls also exhib-
ited reduced expression of Dsg1, Dsc1, and K10 but only after exposure to 3000 J/ m2 UVB. Fur-
ther, the architecture of UV-exposed 3D skin models with shRNA-depleted Dsg1 was significantly
altered compared to controls. Seven days after a single 1000 J/m2 UVB exposure, the thickness of
the living cellular portion of Dsg1-depleted skin models was reduced compared to controls and a
thickened, disorganized stratum corneum had accumulated. Keratinocytes with depleted Dsg1
also exhibited increases in pro- and anti-proliferation proteins including Proliferative Cell Nuclear
Antigen (PCNA) and the Cyclin-Dependent Kinase inhibitor p21, both important for determining
whether cells arrest or proliferate after UV exposure. Thus, loss of Dsg1 disrupts epidermal differ-
entiation following UV exposure and may trigger alterations in cellular proliferation within the skin
structure. These findings have important ramifications for how epidermal recovery proceeds after
UV exposure and how damaged cells are cleared from or retained in the epidermis to later become
cancerous.
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Epidermal growth factor receptor transactivation is suppressed in diabetic wounds, but stim-
ulated by ganglioside depletion
S Lee, H Wilson, X Wang and AS Paller Dermatology, Northwestern University, Chicago, IL
Impaired wound healing in diabetics is associated with diminished insulin receptor (IR)/ insulin-
like growth factor-1 receptor (IGF-1R) signaling. Although epidermal growth factor receptor (EGFR)
activation is also known to promote normal wound healing, its suppression in diabetic wounds has
not been assessed. We have now found a marked diminution in EGFR phosphorylation in wounds
of diet-induced obese diabetic mice in comparison with wounds of control mice, concomitant
with decreased keratinocyte proliferation (p<0.01) and migration (p<0.05), as shown by BrdU label-
ing. The markedly diminished expression of phosphorylated EGFR, and reduced proliferation and
migration are normalized in the wounds of obese GM3 synthase knockout (ganglioside-depleted)
mice. We have also noted that insulin and IGF-1, in addition to EGF, activate EGFR in cultured nor-
mal human keratinocytes. In the presence of 12 mM supplemental glucose, EGFR autophosphory-
lation is diminished and EGFR transactivation by insulin and IGF-1 is totally eliminated. In contrast,
mouse GM3S knockout keratinocytes and human keratinocytes with biochemical suppression of
ganglioside synthesis show a marked increase in EGF-, insulin-, and IGF-1-induced EGFR phos-
phorylation, which is sustained in the presence of high glucose. Treatment of human keratinocytes
with the EGFR inhibitor AG1478 suppresses insulin-induced migration by 49%, but does not inhibit
the migration of ganglioside-depleted keratinocytes. These data suggest a role for insulin-induced
EGFR transactivation in normal wound healing and its suppression in diabetes. The sustained lig-
and- or insulin/IGF-1-induced activation of EGFR by ganglioside depletion, even in the presence of
excess glucose, implicates local ganglioside reduction as a promising therapy for diabetic wounds.
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Transforming growth factor-β1 (TGF-β1)-mediated transcriptional regulation of CXCR4 in
human basal cell carcinoma cells is mediated by extracellular signal-related kinase 1/2 (ERK1/2)
and ETS-1 pathways
S Jee,1 C Chu,1 S Cha,2 H Chiu1 and M Kuo2 1 Dermatology, College of Medicine, National
Taiwan University, Taipei, Taiwan and 2 Graduate Institute of Toxicology, College of Medicine,
National Taiwan University, Taipei, Taiwan
Basal cell carcinoma (BCC) is the most common skin cancer in humans which is characterized by
local aggressiveness with little metastatic potential. Recently, CXCR4 was shown to enhance inva-
siveness and angiogenesis of BCC cells. In our previous study, we also found invasive types (mor-
phea or infiltrative type) of BCCs had frequent high expression of CXCR4 protein as compared to
those of non-invasive types. In this study, we investigated the mechanisms involved in the regula-
tion of CXCR4 expression in invasive type BCCs. We found that invasive type BCC specimens had
higher mRNA levels of transforming growth factor-β1 (TGF-β1) and connective tissue growth fac-
tor (CTGF) than non-invasive type BCCs. Concurrently, non-contact co-culture of dermal fibrob-
lasts with human BCC cells also increased the expression of CXCR4 in human BCC cells. Treatment
of recombinant human TGF-β1, but not CTGF, enhanced the mRNA levels of CXCR4 in time- and
does-dependent manners. The protein level and surface expression of CXCR4 in human BCC cells
were also increased by TGF-β1 treatment. In addition, immunohistochemical studies also revealed
that TGF-β1 was intensely expressed in the surrounding fibroblasts of invasive type BCCs which
was positively correlated with the CXCR4 expression of BCC tumor cells. The transcriptional regu-
lation of CXCR4 by TGF-β1 was mediated by phosphorylation of extracellular signal-related kinase
1/2 (ERK1/2) pathway and subsequent activation of ETS-1 transcription factor. In summary, this study
indicated TGF-β1 mediated invasion of BCC via ERK1/2/ETS-1/CXCR4 signal cascade in context of
interaction between cancer associated fibroblasts and BCC.
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Dermal matrix composition promotes development of aggressive squamous cell carcinoma
in recessive dystrophic epidermolysis bullosa
Y Ng,1,2 C Pourreyron,1 J Salas-Alanis,3 R Cepeda-Valdes,3 W Yan,4 S Wright,1 M Chen,5 F Hogg,1
J McGrath,6 D Murrell,4 I Leigh,1 E Lane2 and A South1 1 University of Dundee, Dundee, United
Kingdom, 2 Institute of Medical Biology, A*Star, Singapore, Singapore, 3 Universidad
Autonoma de Nuevo Leon, Monterrey, Mexico, 4 St George Hospital, UNSW, Sydney, NSW,
Australia, 5 Department of Dermatology, Keck School of Medicine, USC, Los Angeles, CA and
6 King’s College London, London, United Kingdom
Cutaneous squamous cell carcinoma (cSCC) occurs frequently in patients with recessive dystrophic
epidermolysis bullosa (RDEB). Metastasis and mortality in RDEB, however, far exceeds cSCC com-
plications in organ transplant recipients or xenoderma pigmentosum. Here we compare cultured
fibroblasts isolated from RDEB and non-RDEB individuals with no cSCC or from cSCC tumor matrix
using mRNA expression profiling. We show that, unlike keratinocytes analyzed in a similar fash-
ion, RDEB cancer-associated fibroblasts exhibit a distinct and divergent gene expression profile.
We demonstrate that RDEB normal skin fibroblasts share the majority of their gene expression with
cancer-associated fibroblasts. We observed an increase in a large proportion of the differentially
expressed genes involved in matrix and cell adhesion such as ITGA3, ITGA6, COL5A1, COL12A1
and TSP1, which we postulate promotes tumor progression. In support of our hypothesis, we iden-
tify that RDEB cancer-associated fibroblasts confer increased adhesion and invasion to tumor and
non-tumor keratinocytes and show that normal dermal fibroblast siRNA knockdown of COL7A1,
the defective gene in RDEB, yields concurrent increases in type XII collagen and thrombospondin-
1, as well as Wnt-5A. Re-expression of wild type COL7A1 in RDEB cancer-associated fibroblasts
decreases type XII collagen, thrombospondin- 1 and Wnt-5A expression. Overall our data demon-
strate that matrix composition in RDEB is a permissive environment for tumor development and type
VII collagen directly regulates the composition of matrix proteins secreted by dermal and cancer-
associated fibroblasts.
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Genome-wide association studies on human pigmentation traits and non-melanoma skin can-
cer risk
M Zhang,1 F Song,1 A Qureshi,1,2 J Zhang,3 L Liang4,5 and J Han1,2,4 1 Dermatology, Brigham and
Women’s Hospital, Boston, MA, 2 Channing Laboratory, Brigham and Women’s Hospital,
Boston, MA, 3 FAS Research Computing, Harvard University, Cambridge, MA, 4
Epidemiology, Harvard School of Public Health, Boston, MA and 5 Biostatistics, Harvard
School of Public Health, Boston, MA
Multiple Genome-wide association studies (GWASs) have been completed in the Nurses’ Health
Study and the Health Professionals Follow-up Study, accruing more than 15,000 individuals. More
recently, with data released from the 1000 Genomes Project, we imputed about 10 million SNPs
based on the genotyped SNPs and haplotypes from database. Using multiple GWAS sets in both
cohorts with newly imputed data, we conducted GWASs on pigmentary traits, including natural
hair color, eye colors, tanning ability and the number of sunburns, as well as a GWAS on the num-
ber of non-melanoma skin cancer. We performed a meta-analysis to combine the results of all sets.
Using a multistage study design, we identified a new region on chromosome 13q22 associated
with natural hair color. The most significant SNP in this region reached a p-value of 2.4×10-14 (p =
5.4×10-9 in the discovery stage and p = 1.2×10-6 in the replication stage). We newly identified and
replicated a SNP on 1q32.3 associated with brown eye color (p = 7.0×10-8 in the combined set), a
SNP on 5p15 with green eye color (p = 9.1×10-7 in the combined set), and a SNP on 11q25 with
the number of sunburns (p = 5.6×10-6 in the combined set). The SNP associated with the number
of sunburns was also associated with the expression of a local gene based on the transcript expres-
sion profiling data of 87 HapMap CEU cell lines (NCBI GEO database, accession GSE7792). As for
the number of non-melanoma skin cancer GWAS, we identified two independent SNPs on chro-
mosome 6p25. One reached a p-value of 7.2×10-14 (p = 1.8×10-8 in the discovery stage and p =
6.7×10-7 in the replication stage). The other reached a p-value of 5.0×10-8 in the combined set. We
also identified a novel SNP on chromosome 14q22 associated with the number of non-melanoma
skin cancer (p = 6.6×10-8 in the combined set).
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Bulge-derived stem cells form BCC-like tumors upon wounding
SY Wong1,2 and JF Reiter2 1 Dermatology, University of Michigan, Ann Arbor, MI and 2
Biochemistry, University of California San Francisco, San Francisco, CA
Numerous stem cell populations are thought to co-exist in the skin and hair follicle. Whether these
different cell populations are equally susceptible to oncogenic transformation is currently unclear.
Here we show that upon expression of the oncogene SmoM2, hair follicle stem cells located in the
bulge do not form tumors likely due to a restriction in downstream Hedgehog pathway activation.
Upon full thickness excisional wounding, however, oncogene-expressing bulge cells traffic to the
site of injury, gain the ability to activate downstream Hedgehog target genes, and give rise to BCC-
like tumors. These studies suggest that wounding can affect the cell-of-origin of some cancers, and
provide an explanation for why some human BCCs may be associated with injury.
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Human basal cell carcinoma tumor initiating cells express MDR1 and are resistant to etopo-
side killing
CS Colmont,1 A Ben Ketah,1 R Errington,2 CL Yee,3 M Udey,3 JC Vogel3 and GK Patel1 1
Dermatology and Wound Healing, Cardiff University, Cardiff, United Kingdom, 2 Department
of Infection, Immunity & Biochemistry, Cardiff University, Cardiff, United Kingdom and 3
Dermatology Branch, National Cancer institute, NIH, Bethesda, MD
In line with the cancer stem cell model human basal cell carcinoma (BCC) exhibited hair follicle
differentiation with expression of outer root sheath (K5, K14, K16, K17 & K19), companion layer
(K75), inner root sheath (K26, 27, 28, 71, 72 & K74), cuticle (K32 & K82) and matrix (K35 & K85)
but not hair shaft (K31, K22 and K81) keratins. To enrich tumour initiating cells (TIC), cell surface
proteins previously used to isolate the human hair follicle bulge stem cells (CD24, CD71, CD146,
CD200 & CD45) were used to delineate BCC subpopulations. EpCAM+ CD45- BCC cells repre-
sented 49-62% of the viable cells with a small fraction of EpCAM+ CD200+ BCC cells irrespective
of their histological type (1.63 +/- 1.11% (range 3.96 to 0.05%, n=21)). When similar numbers of
freshly isolated unsorted and sorted BCC cells were cultured with irradiated 3T3 feeder cells, CD200+
CD45- cells gave rise to 3-fold more colonies than CD200- CD45- cells (p<0.005), which in turn
gave rise to fewer colonies than unsorted cells (p<0.01). Reproducible in vivo human BCC growth
was only achieved when athymic nude mice were pre-treated with etoposide after creation of a
“humanised” stromal bed into which freshly isolated BCC cells were implanted. Using limiting dilu-
tion analysis, we estimated the TIC frequency in unsorted BCC to be 1 in 2 million cells. In con-
trast, the CD200+ CD45- sorted population resulted in tumor growth with as few as 1000 cells, with
an estimated TIC frequency of 1 in 483 cells - a 4000-fold enrichment (n=10 BCCs). The CD200-
CD45- sub-population was unable to give rise to BCC growth in vivo. BCC cells were resistant to
etoposide killing in vitro through constitutive and induced expression of MDR1. Interestingly, both
MDR1+ CD200+ CD45- and MDR1- CD200+ CD45- subpopulations resulted in tumour growth in
vivo (n=3 BCCs). In conclusion, a minor CD200+ CD45- subpopulation is essential for BCC growth.
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Aldo-keto reductase 1C3 (AKR1C3) is highly expressed in cutaneous squamous cell carci-
noma (SCC) and affects SCC cell proliferation
A Mantel, A Mendini, J Vanbuskirk and AP Pentland Dermatology, University of Rochester,
Rochester, NY
Squamous Cell Carcinoma (SCC) is the second most common non-melanoma skin cancer. SCC can
metastasize and its treatment is costly. AKR1C3 belongs to the superfamily of NAD(P)(H)-depend-
ent AKR enzymes that primarily mediate steroid hormone metabolism. Unlike other AKR1C mem-
bers, AKR1C3 (also termed F synthase) synthesizes PGF2α from PGH2, and metabolizes PGD2 to
9α,11β-PGF2. AKR1C3 promotes malignancies of prostate and breast, suggesting its capacity for sex
hormone synthesis may stimulate proliferation. AKR1C3 also influences some hormone-independ-
ent cancers, suggesting a non-hormonal tumor promoting function. AKR1C3 expression was there-
fore evaluated in 6 SCC and 7 BCC by immunohistochemistry, revealing strong immunoreactivity
for AKR1C3 in the tumor mass of SCC but not BCC. We next established a human SCC cell line.
SCC cells expressed keratin 5, a marker of basal keratinocytes, demonstrated defective terminal dif-
ferentiation, and generated SCC-like tumors when subcutaneously injected into immunodeficient
mice. The SCC cells were then infected with AKR1C3 over-expressing retrovirus or with empty vec-
tor. Over-expression of AKR1C3 in SCC cells was confirmed by western blot. Overexpressing cells
metabolized 12 fold more PGD2 to 9α,11β-PGF2 than controls, an AKR1C3 specific reaction. Next,
the effects of AKR1C3 over-expression on SCC cell proliferation were assessed by Click-iT assay.
Proliferation of overexpressing cells did not change, but cells were 10 fold more resistant to the
antiproliferative effects of PGD2. Untransfected SCC also showed decreased proliferation upon expo-
sure to PGD2 as well as the PPARγ agonist 15d-PGJ2, a non-enzymatic dehydration metabolite of
PGD2. Addition of 9α,11β-PGF2 had no effect. We conclude that AKR1C3 over-expression may pro-
tect SCC cells from the anti-proliferative/pro-apoptotic effects of prostanoid inflammatory media-
tors in the local environment by diverting the metabolism of PGD2 toward the generation of 9α,11β-
PGF2 which does not affect tumor growth.
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MicroRNAs signatures in cutaneous squamous cell carcinomas of immunocompetent and
organ transplant patients
EB Olasz,1 M Neuburg,1 J Lazar,1 NE Duncan,1 AM Schock,1 L Seline,1 A Lopez,1 Y Lu,2 P Liu2 and
Z Lazarova1 1 Dermatology, Medical College of Wisconsin, Milwaukee, WI and 2 Physiology,
Medical College of Wisconsin, Milwaukee, WI
Cutaneous squamous cell carcinoma (CSCC) is the second most common skin malignancy in the
general population and is especially severe in organ transplant recipients (OTRs). MicroRNAs
(miRNAs) are epigenetic regulators of gene expression. Recent studies have shown their involve-
ment in cancer pathogenesis as regulators of tumor growth and metastasis. However, expression
patterns and roles of these miRNAs in CSCC are largely unknown. We hypothesized that CSCC in
the OTRs may have a unique miRNA profile, which may play a critical role in cancer development,
progression, and prognosis. Differential expression of 88 cancer related miRNAs was analyzed using
Human Cancer RT2 miRNA PCR Arrays (SABiosciences) in 44 study participants with CSCC; 32
immunocompetent (IC) patients and 12 OTRs. The expression of miRNAs for all tumor samples was
normalized to four housekeeping genes and compared with those in 15 normal skin samples. To
assess the differences between the groups, nonparametric permutation tests were performed to cal-
culate the p-value for each miRNA. False discovery rate was controlled for multiple testing. Four
miRNAs were significantly upregulated and sixteen were significantly downregulated in CSCCs
taken from IC patients. Two miRNAs were significantly upregulated and seventeen were significantly
downregulated in CSCCs taken from OTRs. Interestingly, direct comparison of differentially expressed
miRNas in IC vs. OTRs identified two significantly downregulated miRNAs (miR-150 and miR-146a)
in OTRs. These miRNAs have been described as potent suppressors of tumor progression and metas-
tasis. Our findings suggest that CSCCs have a unique miRNA profiling pattern and that specific
miRNAs are present in OTRs. This study may provide fundamental information for further investi-
gations of functional roles of miRNAs in CSCC development, progression, and metastasis.
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Manipulating and monitoring Fas expression by cutaneous T-cell lymphoma (CTCL) tumor
cells in vitro and in vivo
J Wu, N Stutz and GS Wood Dermatology, University of Wisconsin Madison and VAMC,
Madison, WI
Previously, we reported that CTCL cells are frequently deficient in Fas protein relative to normal T
cells and that increasing Fas expression can restore sensitivity to Fas-mediated apoptosis. Using
immunoperoxidase methods, we now show that factors downstream of Fas (FADD, procaspases 8
and 3) are all well expressed by CTCL cells. These findings support the potential clinical relevance
of promoting Fas pathway apoptosis in CTCL by enhancing expression of Fas, the key factor defi-
cient in the cascade. We noted earlier that Fas promoter methylation correlates inversely with Fas
expression and that methotrexate (MTX) can reverse this process. Because MTX depletes S-adeno-
syl methionine (SAM), we proposed that MTX acts as a demethylator by blocking synthesis of SAM,
the main methyl donor for DNA methyltransferases. We now show that other folate analogs (peme-
trexed, aminopterin) have the same effects as MTX and that addition of exogenous SAM opposes
MTX-induced demethylation and its associated up-regulation of Fas. These findings support our pro-
posed SAM-related mechanism for the demethylating effects of MTX and related compounds. In
order to determine if the demethylating effects of MTX occur in vivo, we developed a novel method
to monitor Fas promoter methylation in lesional samples from CTCL patients treated with MTX. This
quantitative method involves laser capture microdissection, DNA extraction, bisulfite conversion,
PCR and pyrosequencing. It allowed us to show significant reduction of Fas promoter methylation
in CTCL cells isolated from patients undergoing MTX therapy. Because our method uses formalin-
fixed, paraffin-embedded tissue sections, it allows analysis of the large libraries of archival pathol-
ogy specimens available at most clinical centers and will be useful for a wide variety of DNA methy-
lation studies.
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Histone deacetylase-3 promotes melanoma metastasis by deacetylating ganglioside GM3 and
increases cell proliferation through p70S6 kinase signaling
DQ Bach, Q Yan, J Liu, AS Paller, S Yang, T Traczyk, P Gerami and XQ Wang Dermatology,
Northwestern University, Chicago, IL
GM3, the simplest ganglioside, regulates cell proliferation, migration and invasion by influencing
cell signaling at the membrane level. Although the N-acetylated form of GM3 (c-GM3) is expressed
in most normal cells, deacetylated GM3 (d-GM3) is mainly found in metastatic melanomas. We
have previously found that decreases in d-GM3 reduce melanoma cell proliferation and prevent
growth of melanoma xenografts in mice. However, the human deacetylase that yields d-GM3 and
the signaling pathway that regulates d-GM3-induced melanoma cell proliferation are unknown.
Among all 18 histone deacetylases (HDACs) in melanoma cell lines, we found that HDAC3 is sig-
nificantly increased in d-GM3 positive metastatic melanoma cells as assessed by qPCR. We further
verified the increase in HDAC3 expression in metastatic melanomas by immunohistochemical stain-
ing of tumor sections from patients with metastatic melanomas. Given our previous discovery that
GM3 deacetylation activates ERK-independent p70S6 kinase signaling in a squamous carcinoma
cell line, we hypothesized that HDAC3 deacetylates GM3, which then activates p70S6 kinase sig-
naling to promote melanoma proliferation. We have now shown that knocking down HDAC3 expres-
sion by its specific shRNA inhibits melanoma cell proliferation, and that supplemental d-GM3, but
not c-GM3, reverses the inhibition. HDAC3 knockdown significantly reduces d-GM3 expression in
C8161 melanoma cells based on thin-layer chromatography (TLC) immunostaining. Inhibition of
p70S6K by treatment of the cells with either rapamycin or p70S6K siRNA dramatically decreased
cell proliferation induced by increasing HDAC3 through transfection of cells with HDAC3 cDNA.
These data suggest that HDAC3 plays a crucial role in metastatic melanoma proliferation through
deacetylating GM3, and provides an additional rationale for the use of inhibitors of HDAC3 or d-
GM3 for treating metastatic melanoma.
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Expression of CD10 in squmous cell carcinoma and precancerous lesion
J Lee, J Youn and J Roh Dermatology, Gilhospital, Incheon City, Republic of Korea
Cutaneous squamous cell carcinoma (SCC) is widely accepted to be the result of a transformation
from precancerous lesions, such as actinic keratosis and Bowen’s disease. CD 10 is a zinc-depend-
ent metallopeptidase expressed on the surface of a range of normal and neoplastic cells. Recent
studies have suggested that CD 10 expression is associated with tumor progression and metastasis
in malignant melanoma. This study examined whether CD 10 expression in cutaneous SCC is asso-
ciated with tumor progression and other clinicopathology data. A 2-mm specimen was obtained
from the archival tissues, and then each specimen was placed on the microarray for each disease.
A total of 18 cutaneous SCC samples were immunostained for CD 10 by aforementioned tissue
microarray method. In addition, 29, 28 and 29 cases of actinic keratosis, Bowenoid actinic kerato-
sis and Bowen’s disease, respectively, were immunostained for comparison. The clinicopathology
data, such as age, gender, site, size, duration, recurrence, lymph node metastasis, depth of invasion
and grade of differentiation, were obtained from a chart review and confirmation by two der-
matopathologists. The total area and intensity of the immunostain were arbitrarily defined as fol-
lows: area 0 (<5%), 1 (5~25%), 2 (25%~50%), 3 (50%~75%) and 4 (>75%); and intensity 0 (none),
1 (weak), 2 (moderate) and 3 (severe). The variables were multiplied and classified from 0 to 12
grade. Six out of 18 cases of cutaneous SCC (33%) showed CD 10 expression, whereas no CD 10
expression was observed in the other cancers. There was a positive relationship between CD 10
expression and recurrence, lymph node metastasis and grade of differentiation (P< 0.05 each). CD
10 expression is probably associated with tumor progression, lymph node metastasis and recur-
rence in cutaneous SCC.
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Gene expression profiling of basal cell carcinoma using laser capture microdissection reveals
over-expression of oncogene anaplastic lymphoma kinase
H Ning,1 H Mitsui,1 M Suarez-Farinas,1,2 KR Shah,3 I Coats,1 JA Carucci4 and JG Krueger1 1
Department of Investigative Dermatology, The Rockefeller University, New York, NY, 2 Center
for Clinical and Translational Science, The Rockefeller University, New York, NY, 3 Texas
Dermatology Associates, Baylor University Medical Center, Dallas, TX and 4 Dermatology,
New York University Langone Medical Center, New York, NY
Basal cell carcinoma (BCC), the most common type of skin cancer among Caucasians, is a slow
growing, yet malignant, tumour. It rarely metastasizes and causes death. However, it can cause irre-
versible damage to the surrounding tissue by local invasion. We have analyzed the gene expression
of nodular and infiltrative BCC compared to normal epidermis using microarray analysis after laser
capture microdissection. We found, in both tumour types, a 250 fold (fdr<10-4) upregulation of an
oncogene, anaplastic lymphoma kinase (ALK) and its ligands pleiotrophin (15 fold change, fdr<10-
4) and midkine (20 fold change, fdr<10-4). These findings were confirmed at a genomic level using
quantitative RT-PCR (p<0.05), as well as at a protein level using immunohistochemistry (IHC). In
addition, an antibody against phosphorylated ALK detected positive signals in BCC tumour nests
using IHC, suggesting its activation in BCC. There are many types of cancer that are currently under
clinical trials for ALK inhibitor, with significant tumour reduction in non-small-cell lung cancer. In
a mouse model with ALK overexpression, skin nodules consisting of a hyperplasia of the epidermis
were noted (Giuriato et al, 2010, Blood). These promising data suggest that ALK could be an unrec-
ognized regulatory kinase within epidermal keratinocytes, while its antagonism might be beneficial
in skin neoplasms.
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Inhibitors of oncogenic signal transduction pathways augment the induction of MHC class I
molecules by IFN-γ
BP Pollack1,2,3 and B Sapkota1 1 Dermatology, Emory University, Atlanta, GA, 2 Pathology and
Laboratory Medicine, Emory University, Atlanta, GA and 3 Department of Veterans Affairs,
Atlanta VAMC, Decatur, GA
The main paradigm for the development of targeted anti-cancer therapeutics has centered on the
interplay between oncogenic signaling and tumor cell proliferation/survival. However, it is becom-
ing evident that many targeted therapies have potent immunomodulatory properties suggesting that
they influence the expression of relevant immune system genes. We recently found that epidermal
growth factor receptor (EGFR) inhibitors (EGFRIs) augment the expression of MHC class I and MHC
class II molecules in keratinocytes. Because the EGFR is upstream of several canonical oncogenic
signal transduction pathways, we tested the hypothesis that inhibition EGFR-downstream signaling
pathways would also augment the expression of MHC class I molecules. We used human A431 and
SQCCY1 cells as models for cutaneous and oral squamous cell carcinoma respectively and A375
cells as a model for melanoma. We found that inhibition of the PI3K/mTOR pathway in A431 cells
and SQCCY1 cells with Bez235 augments the induction of MHC class I molecules by IFN-γ. As
expected, no effect was seen in these cell lines using the BRAF-V600E inhibitor PLX4720 as these
cell lines do not express B-RAF-V600E. In contrast, the induction of MHC class I expression by IFN-
γ in A375 cells was unchanged by Bez235 yet augmented by PLX4720. This data supports the con-
cept that oncogenic signaling attenuates the expression of MHC class I molecules via distinct mech-
anisms that are cell type dependent. Further, it supports the notion that targeted therapies may
enhance immune recognition of tumors cells and thus may synergize with immune-based thera-
pies.
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Keratinocyte-specific p38δ mitogen-activated protein kinase (MAPK) deletion reveals a con-
text and gender dependent regulation of skin carcinogenesis
A Kiss,1 AC Koppel,1 J Anders,2 C Cataisson,2 SH Yuspa2 and T Efimova1 1 Dermatology,
Washington University School of Medicine, St. Louis, MO and 2 Laboratory of Cancer Biology
and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD
p38δ MAPK expression and/or activity are increased in human cutaneous malignancies such as
invasive squamous cell carcinoma (SCC) and head and neck SCC, suggesting a role for p38δ in skin
carcinogenesis. We previously reported that mice with germline deletion of p38δ are resistant to
two-stage 7,12-dimethylbenz(a)anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA)
chemical skin carcinogenesis. Here we used conditional gene targeting to study in vivo the ker-
atinocyte-specific function of p38δ in skin tumor development, by subjecting mice lacking p38δ in
keratinocytes (p38δ-ΔK) to a two-stage skin carcinogenesis regimen. Keratinocyte-specific p38δ abla-
tion in vivo did not significantly affect tumor latency, incidence, or multiplicity, but led to signifi-
cantly increased average individual tumor volume in p38δ-ΔK mice relative to wild-type (WT) mice.
The latter parameter was similar between male p38δ-ΔK and WT, but significantly larger in female
p38δ-ΔK relative to female WT mice, highlighting an unexpected gender bias in skin tumor devel-
opment of mutants. These results show that, unlike systemic p38δ deficiency, keratinocyte-specific
inhibition of p38δ signaling does not protect against DMBA/TPA skin carcinogenesis, and suggest
that p38δ may function in other cell types to control skin tumor development in this model system.
However, when v-rasHa-transduced WT and p38δ-null keratinocytes were grafted onto nude mice,
tumor growth was retarded in the absence of keratinocyte p38δ relative to WT cells, suggesting that
keratinocyte p38δ signaling contributes to tumorigenic properties of Ras-transformed keratinocytes
in this experimental context. Taken together with previous data, these results indicate that p38δ con-
tributes both cell autonomous and paracrine effects during the course of skin tumor formation.
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Protein Kinase Cε and its interacting proteins Hsp90β and Stat3 are potential molecular tar-
gets for prevention of ultraviolet radiation-induced cutaneous damage and development of
squamous cell carcinomas
AK Verma, JM Sand, MH Aziz and A Haque Human Oncology, University of Wisconsin
Madison, Madison, WI
Epidermal protein kinase C epsilon (PKCε) level dictates the susceptibility of mice to the develop-
ment of squamous cell carcinomas (SCC) elicited by ultraviolet radiation (UVR). UVR-induced SCC
in PKCε overexpressing transgenic mice, which originates from the hair follicle, is moderately dif-
ferentiated, and rapidly metastasizes. To find clues about the mechanisms by which PKCε sensitizes
skin to UVR carcinogenesis, we found that UVR exposure induces the interaction of PKCε with
heat shock protein (Hsp) 90β. Hsp90 is a ubiquitous molecular chaperone, which may play a role
in the constitutive activation and stability of PKCε. UVR-activated PKCε imparts oncogenic signals,
which include inhibition of apoptosis and increased epidermal cell proliferation. PKCε -mediated
cell survival signal in UVR-induced development of SCC also involves interaction and activation of
signal transducers and activators of transcription-3 (Stat3) and Stat3-regulated genes (c-myc, cyclin
D1, cdc25A, and COX-2). The results indicate that association of Hsp90β with its client PKCε may
be essential for both their maturation into a signaling-competent enzyme and enzyme stability. UVR-
induced enhanced interaction of PKCε with Hsp90β and subsequent constitutive activation of Stat3
appears to be the key components of the mechanism by which PKCε imparts sensitivity to UVR-
induced development of SCC. Taken together, we hypothesize that inhibition of PKCε-Hsp90β and
PKCε-Stat3 interactions are essential for prevention of UVR-induced SCC. The current Hsp90β
inhibitors, which are developed from geldenamycin, and small molecule inhibitors of PKCε-Stat3
interaction are currently being evaluated for prevention of UVR-induced cutaneous damage and
development of squamous cell carcinomas.
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Genetic and chemical knockdown of class III histone deacetylase (HDAC) Sirt1 decreases cel-
lular growth and induces apoptosis in cutaneous T-cell lymphoma (CTCL)
M Nihal,1 N Ahmad1 and GS Wood1,2 1 Dermatology, University of Wisconsin, Madison, WI
and 2 Dermatology, Wm S. Middleton VAMC, Madison, WI
Epigenetic regulation by HDACs affects the growth and viability of CTCL tumor cells. Class I/II HDAC
inhibitors are FDA-approved for CTCL therapy. Earlier we showed that the class III HDAC, Sirt1, is
up-regulated in CTCL. Sirt1 is the best studied member of the Sirtuin (Sir2) family of NAD-depend-
ent HDACs. Using flow cytometry, Western blotting and immunostaining of cytospinned CTCL cells,
we found strong Sirt1 expression among CTCL lines HH, Hut78, MyLa, SeAx and SZ4 in compar-
ison to normal blood lymphocytes. Using immunoperoxidase analysis, CTCL tumor cells in lesional
tissue sections also expressed Sirt1 strongly. Genetic knockdown with shRNA resulted in increased
expression of acetylated p53 and PARP cleavage products, consistent with reduction in cellular
metabolic growth and induction of apoptosis. Tenovin-1 is a benzoylthiourea that reversibly inhibits
class III HDACs Sirt1 and Sirt2. It functions upstream of p53. In a dose-dependent manner, tenovin-
1 reduced the cellular viability as well as expression levels of Sirt1 and subsequent increase in cell
death as evident by cleaved PARP in CTCL cells. Although there was some heterogeneity in the over-
all response, genetic and chemical inhibition of Sirt1 reduced the growth and viability of CTCL
tumor cell lines in association with activation of FoxO3. A combination of class I/II and class III
HDAC inhibitors (vorinostat and tenovin-1, respectively) produced a significantly better inhibition
of growth and increase in apoptosis of Hut78 cells at 48 and 96 hrs compared to either agent alone.
Taken together, our results suggest that Sirt1 is widely expressed in CTCL and that some patients
may benefit more from treatment with a combination of different classes of HDAC inhibitors than
with a single HDAC inhibitor.
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An embryonic tumor suppressor isoform, Δ40p53, stabilizes p53 and suppresses p21 in
melanoma
R Takahashi,1,5,6 SN Markovic2,3,4 and HJ Scrable5,6,7 1 Medical Scientist Training Program, Mayo
Clinic, Rochester, MN, 2 Internal Medicine/ Division of Hematology, Mayo Clinic, Rochester,
MN, 3 Oncology/ Division of Medical Oncology, Mayo Clinic, Rochester, MN, 4 Immunology,
Mayo Clinic, Rochester, MN, 5 Biochemistry and Molecular Biology, Mayo Clinic, Rochester,
MN, 6 Kogod Center on Aging, Mayo Clinic, Rochester, MN and 7 Laboratory Medicine and
Pathology, Mayo Clinic, Rochester, MN
The tumor suppressor p53 is the most frequently mutated gene in human cancers. In malignant
melanoma (MM), however, the frequency of p53 mutations is relatively low suggesting that loss of
p53 function is not a major factor in MM tumorigenesis. Recently identified isoforms of p53 that
can modulate the activity of full-length p53 have led to the idea that non-genomic mechanisms
could cause loss of p53 function especially in cancers like MM in which p53 expression is variable.
We hypothesize that p53 function in MM is specifically altered by Δ40p53, an embryonic isoform
missing the first forty N-terminal amino acids, including the transactivation and Mdm2 binding
domains, of the full-length protein. Δ40p53 has been shown to bind to p53 and alter its tumor sup-
pressor function in mouse embryonic stem cells and in human cancer cell lines. To test this hypoth-
esis, we transduced A375 melanoma cells with a lentivirus encoding Δ40p53. We found that exoge-
nous expression of Δ40p53 stabilized p53 and formed Δ40p53/p53 heterotetramers in the nucleus.
With Δ40p53, DNA synthesis increased and p21 transcript levels decreased. p21 levels were induced
with gamma-irradiation in the absence of Δ40p53, and remained suppressed with Δ40p53. The
nuclear heterotetramers in conjunction with dampened p21 induction suggest that Δ40p53 might
sequester p53 in stable heterotetramers, which lack full transactivation function. Loss of the Mdm2
binding site in Δ40p53 prevents ubiquitination and degradation and in complexes with p53 pro-
longs the half-life of the heterotetramer. Thus the apparent increase in p53 protein level does not
reflect an increase in p53 transcription factor function, but rather a stabilized complex with reduced
function.
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Human bioengineered proteins induce apoptosis in skin cancers
E Pinney,1 M Montes-Camacho,1 R Hoffman,2 M Baumgartner1 and GK Naughton1 1 Histogen,
Inc., San Diego, CA and 2 AntiCancer, Inc., San Diego, CA
There are a number of unique processes seen in the developing fetus that cease post-partum, includ-
ing the fact that tumors rarely form and scar-less wound healing is seen. In addition, cancer lines
have been “reprogrammed” by co-culture with embryonic ECM. Preclinical and in vitro studies were
performed with bioengineered embryonic-like matrix proteins (hECM) to see if they could reduce
or eliminate tumor load or prevent tumor recurrence. hECM is secreted by neonatal cells grown in
a hypoxic microcarrier culture system which upregulates genes associated with stem cell niches in
the body including various laminins, SPARC, and NOTCH2 and induces multipotent stem cell mark-
ers. In the chick allantoic membrane (CAM) assay melanoma tumor load was reduced by up to
80% versus the control (p<0.05) by the addition of lyophilized reconstituted hECM, and a dose
response curve was seen. Similar inhibition was seen with squamous cell carcinoma. In subcuta-
neous mouse experiments, tumor growth was inhibited by 70-90%. Addition of hECM to seeded
tumor cells and circulating tumor cells in the CAM model significantly reduced metastasis to the
developing brains. (P<0.001) hECM treated wounds post resection of tumors resulted in no recur-
rence whereas all control mice had recurrence and expired within 4 months of the resection. The
inhibitory affect is selective for malignant cells and targets rapidly dividing cancer cells and cancer
stem cells through the upregulation of Caspase 9 which induces apoptosis. Through further pro-
cessing, of the secreted hECM raw material, using molecular weight exclusion filters, we have been
able to generate a solution enriched for the low molecular weight species. This further refinement
has increased the activity several fold and allows for I.V. injection. These data show that hECM has
the potential to show benefit in the treatment of various cancers as a tissue filler post tumor removal,
and as an injectable into the tumor site and may be efficacious in treating actinic keratosis and
other skin cancers.
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Next-generation sequencing identifies Notch receptors as integral tumor suppressors in
cutaneous and lung squamous cell carcinomas
NJ Wang,1 Z Sanborn,2 KL Arnett,3 LJ Bayston,3 W Liao,4 CM Proby,5 IM Leigh,3 PB Gordon,6
M Sharma,4 JP North,4 SS Vemula,7 TM Mauro,4 IM Neuhaus,4 PE LeBoit,7 P Kwok,4 ST Arron,4
AE Bale,6 D Haussler,2 JE Cleaver,4 JW Gray,1 PT Spellman,1 AP South,5 JC Aster,3 SC Blacklow3,8
and RJ Cho4 1 OHSU, Portland, OR, 2 UCSC, Santa Cruz, CA, 3 Brigham and Women’s
Hospital, Boston, MA, 4 UCSF, San Francisco, CA, 5 University of Dundee, Dundee, United
Kingdom, 6 Yale, New Haven, CT, 7 San Francisco Dermatopathology Service, San Francisco,
CA and 8 Dana Farber, Boston, MA
Though squamous cell carcinomas (SCCs) are one of the most frequent forms of epithelial malig-
nancy, few causative mutations have been identified other than p53. Utilizing next-generation
sequencing, we identified loss-of-function NOTCH1 or NOTCH2 mutations in a large percentage
of cutaneous SCCs (cSCCs) and in a lesser fraction of lung SCCs. Notch activation by fixed, envi-
ronmental ligands normally initiates a transcriptional program determining cell fate, growth, and
survival. Our reported Notch mutations result in aberrant proteins unable to properly respond to
external stimuli and initiate signaling. In contrast, Notch aberrations in lymphoma and leukemia
are constitutively active. These results point to a unique, dual role for Notch proteins in cancer pro-
gression as both tumor suppressors and oncogenes, and caution that pathway inhibitors should be
closely monitored for promotion of epithelial malignancies. We further report here that whole genome
sequencing has elucidated aspects of timing of Notch loss during tumorigenesis. Expanded muta-
tion and expression analysis in cell lines also reveals mechanisms of phenocopy, emphasizing the
critical role of Notch loss.
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Transcriptomal analysis in basal cell carcinoma provides insights into the genetic basis of dis-
ease
ER Heller,1 A Gor,1 D Wang,2 Q Hu,2 M Katdare,3 S Liu2 and AA Sinha1 1 Dermatology,
University at Buffalo and Roswell Park Cancer Institute, Buffalo, NY, 2 Biostatistics, Roswell
Park Cancer Institute, Buffalo, NY and 3 Skin of Color Research Institute, Hampton University,
Hampton, VA
We employed genome wide microarray analysis to determine transcriptomal profiles in BCC. This
data was used to 1) classify samples based on phenotype via hierarchical clustering methods, 2)
functionally annotate pathways important to BCC pathogenesis, and 3) compare genetic informa-
tion to our transcriptional data in order to identify potential genetic risk factors. A gene signature
comprised of 331 differentially expressed genes (DEGs) was generated comparing 4 lesional and 4
site-matched control samples using the Affymetrix Human Genome U95A microarray platforms.
Hierarchical clustering based on the obtained gene signature separated the samples into their cor-
responding phenotype. Functional annotation and pathway analysis identified multiple dysregu-
lated pathways, including those involved in PPAR-γ signaling, TGFβ signaling, and lipid metabo-
lism. BCC-associated DEGs were mapped to previously reported BCC susceptibility loci including
1p36, 1q42, 5p13.3, 5p15 and 12q11-13. Our analysis also revealed transcriptional “hot spots” on
chromosome 5 which help to confirm (5p13 and 5p15) and suggest novel (5q11.2-14.3, 5q22.1-
23.3, and 5q31-35.3) disease susceptibility loci/regions. By integrating transcriptional data with
genomic information, our study reveals potential susceptibility loci/regions associated with basal
cell carcinoma in terms of altered gene expression. Detailed characterization of the genetic and
transcriptional alterations associated with BCC development may facilitate the development of novel
therapeutic modalities focused on specific and individualized targets.
137
Dual role of apoptosis-associated speck-like protein containing a CARD (ASC) in tumorige-
nesis of human melanoma
W Liu,1 JH Dunn,1 DA Norris,1 CA Dinarello2 and M Fujita1 1 Dermatology, University of
Colorado, School of Medicine, Aurora, CO and 2 Medicine, University of Colorado, School of
Medicine, Aurora, CO
ASC (apoptosis-associated speck-like protein containing a CARD) was originally named because of
its ability to induce apoptosis when overexpressed in certain tumor cell lines. As an integral com-
ponent of the inflammasome, ASC also mediates inflammatory signals. We have previously reported
that inflammasome is consititutively active in human melanoma cells. However, the role of ASC
protein in tumorigenesis remains unclear. Here we examined the role of ASC in tumorigenesis of
primary and metastatic human melanoma cells. ASC protein expression was high in primary
melanoma cells and relatively low in metastatic melanoma cells. While overexpression of ASC in
metastatic melanoma induced no change in cell viability, silencing ASC with short hairpin RNA
reduced cell viability and tumorigenesis in metastatic melanoma. On the other hand, silencing
ASC enhanced cell viability and tumorigenesis in primary melanoma. In primary and metastatic
melanoma cells, ASC knockdown inhibited inflammasome-mediated caspase-1 activity and IL-1β
secretion. However, despite the interaction of ASC with IKKα/β in both primary and metastatic
melanoma cells, phosphorylated IKKα/β expression and NF-κB activity were suppressed in metasta-
tic melanoma cells and enhanced in primary melanoma cells after ASC knockdown. To our knowl-
edge, this is the first report to examine expression-dependent and/or stage-dependent roles of ASC
in cancer cells. These findings implicate a dual role of ASC in tumorigenesis. High levels of ASC
expression in primary melanoma appear to inhibit tumorigenesis, by inhibiting NF-κB activity through
phosphorylation of IKKα/β. On the other hand, the inhibitory effect of ASC in metastatic melanoma
is minimal because of intrinsically low expression of ASC in these tumor cells. Lower levels of ASC
in metastatic melanoma induce tumorigenic pathways by mediating caspase-1-dependent matura-
tion and secretion of IL-1β and enhancing autoinflammatory NF-κB activity.
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Establishment of an organotypic model mimicking arsenic-induced Bowen’s disease
H Yu,1 W Liao,2 J Lu,1 C Lan,1 C Lee1 and C Chang1 1 Department of Dermatology, Kaohsiung
Medical University, Kaohsiung, Taiwan and 2 Department of Biotechnology, Kaohsiung
Medical University, Kaohsiung, Taiwan
Although arsenic has been classified as a human carcinogen, evidences of direct arsenic involve-
ment in carcinogenesis using cell culture or animal model remain limited. Arsenic-induced Bowen’s
disease (As-BD) is a major and early form of arsenical skin cancer presenting pathological charac-
teristics including acanthosis (increased proliferation), dysplasia (loss of identity and polarity), and
dyskeratosis (individual keratinocyte apoptosis). In the present study, we established a skin equiva-
lent model which reproduces the pathognomic manifestations of As-BD that has never before been
produced in laboratory models. We found that arsenic induced keratinocyte centrosome abnor-
malities (multiple in number), G2/M arrest and apoptosis. In this model, arsenic-induced TNF-α
release plays regulatory roles in increasing keratinocyte survival. TNF blocking showed a signifi-
cant decrease in epidermal thickness but did not completely reverse dysplasia. TNF-α increased
arsenic-induced centrosome amplification, decreased G2/M cell cycle arrest and apoptosis. Increased
TNF-α was correlated with increased NF-κB and FLIP-associated caspase-8 inactivation which
resulted in anti-apoptotic response in keratinocytes. In addition, decreased p53 and p21 were also
detected, which might increase the ability of keratinocyte to escape the G2/M cell cycle checking.
We believe that TNF-α involves the pathological characteristics of acanthosis and dysplasia in our
system. Our findings provide a new insight for understanding the early epidermal carcinogenic mod-
ulation by arsenic.
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Identification of protein kinase C activating phorbol ester and ingenol derivatives as candi-
dates for cutaneous P-glycoprotein absorptive transport across the epidermis
L Li, M Ansbro, S Shukla, S Ambudkar, P Blumberg and SH Yuspa LCBG, NCI, Bethesda, MD
P-glycoprotein (P-gp/MDR1/ABCB1) is a membrane-associated multidrug transporter of the ABC
transporter family that facilitates the multidrug resistance of cancer cells when upregulated. P-gp is
also expressed in normal tissue including skin, liver, kidneys, and some endothelial cells. We recently
reported that ingenol 3-angelate (Ing3A), a PKC agonist currently in clinical trials for topical treat-
ment of squamous cell carcinoma, basal cell carcinoma, and actinic keratosis, acts via a P-gp-
dependent mechanism when applied topically in mouse models. In contrast with phorbol 12-myris-
tate 13-acetate (PMA) topical treatment, in which PKC activation remains localized in the epidermis,
Ing3A spans through the epidermis via P-gp mediated skin absorptive transport to activate PKC in
the dermis. This potent PKC activation damages tumor vasculature and establishes the use of an
active P-gp mechanism as a novel therapeutic treatment for skin cancer. In our current study, 11
phorbol ester and ingenol derivatives were evaluated for their ability to function as P-gp sub-
strates/inhibitors. P-gp inhibitory activities of the compounds were measured by calcein AM efflux
assays. The compounds were also tested for their ability to shift drug sensitivity to doxorubicin in
HCT-15 P-gp overexpressing cells. Three phorbol ester derivatives and one ingenol derivative dis-
played P-gp inhibitory activities. Direct interaction of the four compounds with P-gp was demon-
strated in a photoaffinity labeling assay in which the derivatives competitively blocked the substrate
[125I]iodoaryazidoprazosin (IAAP) from binding P-gp. In silico analysis of the phorbol ester and
ingenol derivatives calculated hydrophilicity of each compound and computed LogP values rang-
ing from -0.56 to 8.78. P-gp substrate/inhibitor activities of the four compounds displayed no cor-
relation in hydrophilicity. These compounds are new therapeutic candidates for P-gp mediated skin
absorptive transport.
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Akt and keratin intermediate filaments collaborate to regulate autophagy and tumorigenesis
RC Wang,1 Y Wei,2 Z Zou,2 Z An,2 G Bhagat,3 M White,4 J Reichelt5 and B Levine2 1 Dermatology,
UT Southwestern, Dallas, TX, 2 Internal Medicine, UT Southwestern, Dallas, TX, 3 Pathology
and Cell Biology, Columbia, New York, NY, 4 Cell Biology, UT Southwestern, Dallas, TX and 5
Institute of Cellular Medicine, University of Newcastle, Dallas, TX
Aberrant signaling through the class I phosphatidylinositol 3-kinase (PI3K)-Akt axis is one of the
most frequent alterations in human cancers. Here we show that Akt phosphorylates and inhibits
Beclin 1, an essential autophagy and tumor suppressor protein. The expression of a Beclin 1 mutant
resistant to phosphorylation by Akt increases autophagy, reduces anchorage-independent growth
in vitro, and inhibits Akt-mediated tumorigenesis. Akt phosphorylation of Beclin 1 promotes the
formation of a complex with 14-3-3 and intermediate filament proteins, including keratin 10. A non-
phosphorylatable mutant of Beclin 1 can bind neither 14-3-3 nor keratins. Moreover, a mutant of
keratin that cannot bind 14-3-3 also fails to interact with Beclin 1. The disruption of this complex
through depletion of keratin 10 in vitro or through genetic deletion of keratin 10 in stratified squa-
mous epithelium in vivo results in increased autophagy. Thus, Akt-mediated phosphorylation of
Beclin 1 functions in autophagy inhibition and oncogenesis, and leads to the formation of an
autophagy-inhibitory Beclin 1/14-3-3/type I keratin intermediate filament complex. These findings
have broad implications for understanding the role of Akt signaling and intermediate filament pro-
teins in the regulation of autophagy and cancer.
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Ser727 phosphorylation in STAT3 plays a crucial role in cell survival and nuclear transloca-
tion of STAT3 in human melanocytes and melanoma cells
M Oka,1 M Sakaguchi,1 T Iwasaki,2 Y Fukami2 and C Nishigori1 1 Division of Dermatology,
Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan
and 2 Research Center for Environmental Genomics, Organization of Advanced Science and
Technology, Kobe University, Kobe, Japan
The transcription factor signal transducer and activator of transcription 3 (STAT3) has two important
phosphorylation sites, Tyr705 and Ser727, for its activation. Ser727 phosphorylation has been con-
sidered to be a secondary event after Tyr705 phosphorylation. In this study, the role and regulation
of Ser727 phosphorylation in STAT3 in melanocytic cells were examined. STAT3 was phosphory-
lated on Ser727 in the absence of Tyr705 phosphorylation in melanocytes. 12-O-tetrade-
canoylphorbol-13-acetate-induced increase in cell survival activity and nuclear translocation of
STAT3 was associated with Ser727 phosphorylation. Ser727 was constitutively phosphorylated in
all melanoma cell lines examined irrespective of Tyr705 phosphorylation. The possible involve-
ment of Ser727 phosphorylation in STAT3 in cell survival activity and nuclear translocation of STAT3
in melanocytes was demonstrated also in melanoma cells. The constitutive Ser727 phosphorylation
in melanoma cells was partially mediated by the B-Raf–MEK–ERK1/2 pathway. Immunohistochemical
studies on melanoma specimens of primary lesions of acral lentiginous melanoma revealed that
Ser727 phosphorylation precedes Tyr705 phosphorylation in the early stages of melanoma pro-
gression. Our results indicate that Ser727 phosphorylation on STAT3 is not necessarily a secondary
event after Tyr705 phosphorylation and suggest that Ser727 phosphorylation plays a role in the reg-
ulation of cell survival activity and nuclear translocation of STAT3 in melanocytic cells.
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Elevated epidermal thymic stromal lymphopoietin levels prevent skin tumorigenesis
S Demehri,1,2 A Turkoz,2 LJ Yockey,2 M Turkoz2 and R Kopan2,1 1 Medicine Division of
Dermatology, Washington University, St. Louis, MO and 2 Developmental Biology,
Washington University, St. Louis, MO
Thymic Stromal Lymphopoietin (TSLP) is an epithelial-derived cytokine implicated in induction of
T helper 2 (Th2)-mediated allergic inflammation. Recently, several studies have shown that the Th2
milieu created by TSLP expression in tumor microenvironment stimulates tumor growth and metas-
tasis. Surprisingly, we have discovered a novel tumor suppressor function for TLSP-induced Th2
microenvironment in skin tumorigenesis. Studying mice with clonal loss of Notch signaling in their
skin revealed that high levels of TSLP released by the barrier-defective epidermis led to a severe
atopic dermatitis (AD)-like skin inflammation and resistance to skin tumorigenesis. This tumor resist-
ance phenotype was accompanied by a gradual elimination of Notch-deficient epidermal cells and
their replacement by neighboring wild-type cells over time. Interestingly, blunting the AD-like inflam-
mation by blocking the response to TSLP resulted in an aggressive expansion of Notch-deleted epi-
dermal clones and spontaneous tumorigenesis in Notch-deficient animals. We found that CD4+ Th
cells were both required and sufficient to mediate the effects of TSLP on tumor resistance and skin
rejection in Notch-deficient mice. Moreover, chemical and genetic upregulation of epidermal TSLP
expression in wild-type animals led to their marked resistance to skin tumorigenesis. Taken together,
these findings demonstrate that Th2 response downstream of TSLP leads to the rejection of Notch-
deficient skin and prevents skin tumorigenesis. Considering the emergence of TSLP as a potential
new therapeutic target in treatment of solid cancers, this report points to a novel role for TSLP as an
anti-tumor immune factor that can be utilized to optimally combat and ultimately prevent solid can-
cers.
143
Edar signaling promotes epithelial tumor growth via stimulation of Hedgehog pathway upon
BMP inhibition in the skin
AN Mardaryev,1 I Malashchuk,1 TY Sharova,2 AA Sharov2 and VA Botchkarev1,2 1 Centre for Skin
Sciences, University of Bradford, Bradford, United Kingdom and 2 Dermatology, Boston
University, Boston, MA
Bone morphogenetic protein (BMP) signaling exhibits a potent anti-tumor activity in the skin and
other organs. However, molecular mechanisms underlying tumor-suppressor function of BMP sig-
naling remain poorly understood. Previously, using mice overexpressing BMP antagonist Noggin,
we showed that BMP pathway inhibits initiation and progression of trichofolliculoma-like skin tumors
via antagonizing Wnt and Hedgehog pathways (Amer J Pathol, 2009, 175, 1303). Whereas Nog-
gin-induced activation of Wnt signaling was mediated, at least in part, via decrease of expression
of the Wnt antagonist and BMP target gene Wif1, the mechanism underlying activation of Hedge-
hog signaling pathway in K14-Noggin skin remained elusive. Presently, we observed an increased
expression of Edar transcripts and protein in trichofolliculoma-like tumours in K14-Noggin mice.
To identify the impact of Edar signaling on tumor growth, we generated compound K14-Noggin/down-
less mice bearing an inactivating point mutation in the Edar gene. Whereas tumor initiation process
was not affected in K14-Noggin/downless mice, tumor growth in these mice was significantly retarded
compared to K14-Noggin mice. Retardation of tumor growth in K14-Noggin/downless mice was
associated with decreased cell proliferation and XIAP expression without increase of apoptosis. Fur-
thermore, expression profiling revealed a marked decrease in expression of several members of the
Hedgehog signaling pathway, including Shh, Smo, Ptch1, Gli1 in in K14-Noggin/downless mice
compared to K14-Noggin mice. Taken together, this study demonstrates that BMP pathway nega-
tively regulates Edar signaling in the follicular epithelium and prevents Edar-induced activation of
Hedgehog pathway, thus uncovering an important link in the BMP-mediated tumor suppressor mech-
anisms in cutaneous epithelial cells.
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Receptor-type protein tyrosine phosphatase-beta (RPTP-β) regulation of Met function in squa-
mous cell carcinoma
Y Xu,1 J Zhou,1 TE Carey,2 JJ Voorhees1 and GJ Fisher1 1 Department of Dermatology, University
of Michigan, Ann Arbor, MI and 2 Department of Otorhinolaryngology, University of
Michigan, Ann Arbor, MI
Hepatocyte growth factor receptor (HGFR or “Met”) is a receptor-type protein tyrosine kinase with
known oncogenic property and plays important roles in both progression and metastasis of squa-
mous cell carcinoma (SCC). Activation of Met occurs through self-phosphorylation of specific tyrosines
within Met. These phospho-tyrosines promote assembly of intracellular protein complexes that trans-
mit downstream signals. Activation of Met is regulated by receptor-type protein tyrosine phosphatase-
beta (RPTP-β), which directly dephosphorylates Met. We have investigated regulation of Met-medi-
ated signaling and functions by RPTP-β in human SCC cell lines. RPTP-β expression was dramatically
down-regulated (reduced more than 95%, N=3-5, p<0.05) in two metastatic SCC cell lines, com-
pared to patient-matched SCC cell lines derived from primary tumors. Adenovirus-mediated expres-
sion of RPTP-β in a metastatic SCC cell line decreased HGF-induced Met tyrosine phosphorylation
by 65% (N=3, p<0.05), and reduced down-stream MEK and ERK activation by 70% (N=3, p<0.05)
and 75% (N=3, p<0.05), respectively. Consequently, HGF-mediated cell migration and invasion
(measured by scratch assay and matrigel invasion assays, respectively) were also significantly sup-
pressed. In contrast, knockdown of endogenous RPTP-β by lentivirus-mediated shRNA in a patient-
matched SCC cell line from primary tumor, potentiated HGF-induced Met tyrosine phosphoryla-
tion by 2 fold (N=3, p<0.05), elevated down-stream MEK (1.5 fold N=3, p<0.05) and ERK activation
(1.5 fold N=3, p<0.05), and stimulated cell migration, and invasion. Taken together, these results
demonstrate the importance of RPTP-β in SCC tumor biology, including cell migration and inva-
sion/metastasis, via direct dephosphorylation of Met and regulation of down-stream signal trans-
duction pathways. RPTP-β expression levels, which inversely reflect Met activity, may serve as a
novel bio-marker for SCC progression and metastasis.
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A topical PI3K/mTOR inhibitor induces regression of squamous cell carcinomas in K14-Fyn
Y528F mice
X Yang,1 C Marshall,1 T Dentchev,1 T Salah,1 F Stauffer,2 F Kalthoff3 and J Seykora1 1 Derm., Univ.
of Penn., Philadelphia, PA, 2 NIBR, Basel, Switzerland and 3 ATI-Derm., NIBR, Vienna, Austria
Cutaneous squamous cell carcinoma (cSCC) is the second most common human cancer. Human
cSCCs demonstrate activation of oncogenic signaling pathways that include the Erk 1/2,
PI3K/Akt/mTOR, and Src tyrosine kinases and phospho-STAT3. The K14-Fyn Y528F transgenic mouse
is a model of cSCC that develops pre-cancerous lesions and cSCCs resembling human lesions with
activation of the same signaling pathways. We asked if a topically applied inhibitor of the PI3K/mTOR
pathway would induce regression of cSCCs in K14 Fyn Y528F mice. To test this, 6-week-old cohorts
of K14-Fyn Y528F mice were treated with a 0.6% gel containing DPT-NX7, a small molecule kinase
inhibitor with nanomolar potency against mTOR and class I PI3K kinases, or a control gel. The
DPT-NX7-treated cohort contained 11 mice with 34 cSCCs while the control cohort contained 11
mice with 32 cSCCs. The size of each SCC was measured using calipers before treatment and weekly
thereafter. cSCCs varied from 8-166 mm2 in size, and the size range of cSCCs in each cohort was
similar. The gels were applied to lesions daily Mo-Fr. DPT-NX7 treatment decreased tumor size
56% after two weeks of treatment while tumor size increased 15% in controls (p < 0.001). After five
weeks, tumor size decreased 96% in the DPT-NX7 cohort and 74% of cSCCs regressed completely.
In contrast, the overall size of lesions decreased 35% in the control cohort which is considered to
be a function of age. Evaluation of regressing cSCCs demonstrated residual epidermal hyperplasia,
minimal inflammation, and no ulceration. Immuno-histochemical analysis of DPT-NX7-treated
lesions demonstrated normalization of phosphorylation levels of S6 kinase, STAT-3, and PDK-1 com-
pared to control cSCCs. In summary, topical DPT-NX7 gel induced near complete cSCC regression
in the K14-Fyn Y528F model without prominent inflammation or ulceration. These data suggest
that topical application of potent dual PI3K/mTOR inhibitors may be useful for treating cSCCs.
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TOX, PLS3, and KIR3DL2 genes are differentially expressed in Sézary Syndrome
BL O’Neill, E Mirvish, R Pomerantz, LD Falo and LJ Geskin Dermatology, University of
Pittsburgh, Pittsburgh, PA
Genomic analyses of malignant cells in Sézary Syndrome (SS), the leukemic form of cutaneous T-
cell lymphoma (CTCL), have yielded highly varying results. The majority of published studies relied
on mixtures of peripheral blood mononuclear cells (PBMC) from SS patients and mixed cell popu-
lations derived from skin samples of patients with mycosis fungoides, a distinct form of CTCL. We
hypothesized that genetic signatures for SS may be revealed by comparison of isolated highly puri-
fied Sezary cells and matched non-malignant CD4+ T-cells from the same patients. Our aim was to
generate gene expression data using this novel approach to identify differentially expressed genes
in SS. The results of this study and results obtained from next generation sequence-based transcrip-
tome analysis were analyzed. Using our expression data and an extensive literature review of pre-
viously published SS gene expression studies, we identified putative biomarkers and oncogenes.
Among these were TOX, PLS3, PDCD6, KIR3DL2, and Integrin-β1. PLS3 was identified as highly
upregulated in our study and has been consistently upregulated in published data sets. TOX is a
recently described transcription factor, and SS cell specific upregulation of TOX was uniquely iden-
tified in our study. Dysregulation of KIR3DL2, PDCD6, and Integrin-β1 has been reported in some
studies but not others. We isolated CD4+ cells from fresh blood of SS patients and normal controls
using a sequential ficoll gradient / MACS magnetic bead separation strategy and confirmed the purity
of these populations by flow cytometry. RNA was isolated and quantitative real-time-RT-PCR expres-
sion analysis of TOX, PLS3, PDCD6, KIR3DL2, and Integrin-β1 was performed. Results confirmed
SS-specific upregulation of TOX, PLS3, and KIR3DL2. However, neither PDCD6 nor Integrin-β1
showed differential expression in SS patients. These results substantiate the proposed up regulation
of TOX, PLS3, and KIR3DL2 in malignant cells of SS patients, and support their potential role in SS
pathogenesis and potential utility for the molecular diagnosis of SS.
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Induction of the p16Ink4a/Rb pathway by IFN-γ-mediated tumor immune responses
M Hahn,1 T Wieder,1 H Braumüller,1 E Brenner,1 K Schilbach2 and M Röcken1 1 Dermatology,
University of Tübingen, Tübingen, Germany and 2 General Pediatrics, Oncology/Hematology,
University of Tübingen, Tübingen, Germany
The p16Ink4a/Rb signaling pathway negatively regulates the cell cycle and is frequently impaired
in various cancers, including HPV-positive epithelial cancers. In RIP1-Tag2 mice, the expression of
T antigen (Tag) under control of the rat insulin promoter (RIP) seriously impairs the p16Ink4a/Rb
pathway in pancreatic beta cells. Therefore, RIP1-Tag2 mice undergo multistage carcinogenesis and
develop beta cell cancer. We previously reported that Tag-specific Th1 cells prolong the life of
RIP1-Tag2 mice and inhibit tumor progression in the absence of tissue destruction. Instead, Th1 cells
reduce tumor growth in vivo in an IFN-γ- and TNF-dependent manner. To unravel the mechanisms
that inhibit tumor progression, we investigated the role of the Th1 cell treatment on the aberrant
p16Ink4a/Rb pathway, responsible for the tumor growth in RIP1-Tag2 mice. Ki67-staining revealed
that treatment of mice with Tag-Th1 cells dramatically reduced the proliferation of the tumor cells
in vivo. Simultaneously, the treatment induced p16Ink4a in the tumor cells. As in vivo the two Th1
cytokines IFN-γ and TNF are needed for a successful immune therapy, we studied the influence of
recombinant IFN-γ on RIP1-Tag2 tumor cells in vitro. Indeed, IFN-γ reduced tumor cell prolifera-
tion and strongly increased the cell fraction expressing senescence-associated beta-galactosidase
activity. Further experiments showed that IFN-γ enhanced the expression of p16Ink4a and reduced
the phosphoRb/Rb ratio. Silencing of p16Ink4a by lentiviral infection with shRNA enhanced the
proliferation of the isolated tumor cells thereby demonstrating a link between p16Ink4a induction
and tumor growth arrest. Moreover, we found an IFN-γ-induced, p16Ink4a-mediated growth inhi-
bition in the human rhabdomyosarcoma cell line A204. Therefore, our data suggest that Th1 cell-
based immunotherapy of malignant tumors involves IFN-γ-mediated growth arrest through activa-
tion of the p16Ink4a/Rb pathway.
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Identification of cell cycle- and cancer-associated gene networks activated by Dsg2 using
global cDNA microarray: Crosstalk between Dsg2 and cystatin A
A Gupta, D Brennan, KE Scott, S Addya, JK Wahl, NA Riobo and M Mahoney Dermatology and
Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA
Understanding the molecular basis of keratinocyte growth and survival and the mechanisms of malig-
nant transformation is paramount for early detection and treatment of epithelial-derived cancers.
Substantial evidence supports important roles for desmosomal proteins in skin cancer development.
Here, by global cDNA microarray analysis, we demonstrate that overexpression of Dsg2 in trans-
genic mice caused profound changes in the transcriptome of keratinocytes; whereby, 492 genes
were up- or down-regulated by more than 2-fold. Subsequent GeneSpring analysis identified a num-
ber of these genes to be involved in cell cycle- and cancer-associated gene networks, including
cyclin dependent kinases, S100 Ca2+ binding proteins, and cystatin A (CSTA). CSTA, a cysteine pro-
tease inhibitor expressed in the cornified cell envelope, is known to possess anti-apoptotic activity;
and similar to Dsg2, CSTA is upregulated in several epithelial-derived malignancies, including squa-
mous cell carcinomas. More recently, loss-of-function mutations in the CSTA gene were found to
be the underlying cause of Exfoliative Ichthyosis, which is characterized by disrupted desmosomes
and loss of cell-cell adhesion in the deep epidermis. We confirmed the upregulation of Csta in
response to Dsg2 by qPCR (Csta1, 113.2±2.2; Csta2, 1227.0±1.4; and Csta3, 27.0±0.4) and West-
ern blot. Furthermore, immunostaining showed dramatic increase in expression of Csta throughout
the epidermis of Dsg2 Tg mice. In A431 cells, knockdown of either Dsg2 or CSTA by siRNA or shRNA
reduced cell-cell adhesiveness as measured by the dispase-based dissociation assay. This effect was
additive and synergistic. In summary, these results offer a novel pathway of CSTA regulation involv-
ing Dsg2 by which their active crosstalk may regulate cell adhesion and dysplastic changes possi-
bly creating an imbalance between the proteases and their respective cystatin inhibitors in the skin.
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Successful treatment of human cutaneous T cell lymphoma xenografts by potassium antimonyl
tartrate
A Tun-Kyi,1 PA Oberholzer,2,3,4 J Qin,5 MB Karpova,6 AA Navarini,6 U Ungethüm,6 R Dummer6
and U Döbbeling6 1 Harvard Medical School, Boston, MA, 2 Broad Institute, Cambridge, MA,
3 Dana-Farber Cancer Institute, Boston, MA, 4 Inselspital - University of Bern, Bern,
Switzerland, 5 Loyola University Medical Center, Maywood, IL and 6 University Hospital
Zurich, Zurich, Switzerland
Mycosis fungoides (MF) and its leukemic counterpart Sézary syndrome (SzS) are the most frequent
cutaneous T cell lymphomas (CTCL). There is no cure for these diseases, which makes the devel-
opment of new therapies imperative. Potassium antimonyl tartrate (PAT) has been shown to have
cytotoxic effects on lymphoma and leukemia cell lines. MF and SzS cells express the constitutively
active transcriptions factors nuclear factor kappa B (NFkB), STAT3, STAT5, which promote the expres-
sion of various anti-apoptotic genes. Thus we investigated if PAT can inhibit the binding activities
of these transcription factors and thereby decrease the expression of anti-apoptotic proteins, shift-
ing the balance in favor of cell death. We found that PAT treatment induced apoptosis in CTCL cells
in a concentration dependent manner. Furthermore, PAT induced a reduction of the DNA-binding
activities of the NF-kB subunits p65, p52, RelB and c-Rel as well as of STAT3, STAT5a and STAT5b.
This coincided with a decrease of the anti-apoptotic proteins Bcl-2, Bcl-xL and Mcl-1 and an increase
of apoptosis inducing reactive oxygen species (ROS). Treatment of mice bearing MF xenografts
with daily intralesional injections of PAT achieved complete remission in all animals without reoc-
currence. Higher PAT concentrations were associated with a faster remission time. PAT treated tumors
showed decreased levels of Bcl-2, Bcl-xL and Mcl-1. Primary CTCL tumors showed a constitutive
expression of p-STAT3, p-STAT5, and p-JAK2, and therefore might be suitable as targets for PAT treat-
ment. Consequently, we suggest that PAT could be used as a novel approach in the treatment of
CTCL.
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MiR-223 has altered expression and affects cell growth in mycosis fungoides/cutaneous t-
cell lymphoma
LY McGirt,1 JA Zic1 and CM Eischen2 1 Medicine/Dermatology, Vanderbilt University,
Nashville, TN and 2 Pathology, Microbiology and Immunology, Vanderbilt University,
Nashville, TN
MicroRNA (miRNA) are small, 18-22bp, non-coding RNA known to play a role in malignancy, and
have altered expression in cutaneous T-cell lymphoma (CTCL). We hypothesized that the altered
expression of specific miRNA in mycosis fungoides (MF) plays a role in oncogenesis or progression
of malignancy through effects on their target genes. Frozen, banked skin biopsies of MF and nor-
mal skin controls were evaluated for miRNA expression through quantitative real-time PCR. The
CTCL cell line, HH, was utilized for transfection with miRNA mimic, and cell growth was analyzed
through a cell viability assay. Decreased expression of miR-223 was detected in MF skin biopsies
as compared to normal controls (miR-223 relative expression: 5.72 +/- 1.73 vs 29.97 +/- 9.78,
p<0.0001). There was also decreasing miR-223 expression as the MF stage advanced (stage Ia-IIa:
10.63 +/- 3.96; stage IIb-IV: 3.74 +/- 1.71, p=0.07). Transfecting HH cells with miR-223 mimic
resulted in increased miR-223 expression and decreased cell growth when compared to control at
96 hours post transfection (8.5x105/mL vs 10.9x105/mL, p=0.04). Additionally, evaluation of mRNA
expression of the miR-223 target genes E2F1 (transcription factor involved in cell cycle control) and
MEF2C (transcription factor oncogene) revealed decreased expression after transfection with miR-
223 mimic versus control (E2F1 relative expression: 0.012 +/- 0.0003 vs 0.022 +/- 0.001, p=0.002;
MEF2C relative expression: 0.008 +/- 0.001 vs 0.019 +/- 0.003, p=0.03). These results reveal an
altered expression of miR-223 within MF/CTCL that may have a significant role in oncogenesis or
progression of disease, and may provide future therapeutic targets.
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Investigating the capacity of two-photon confocal microscopy to monitor the uptake, local-
ization, and efflux of polyaromatic hydrocarbons in Langerhans cells
J Lewis, P Zhao, R Filler and M Girardi Yale School of Medicine, New Haven, CT
We previously demonstrated that skin lacking Langerhans cells (LC) was resistant to DMBA/TPA-
induced two-stage chemical carcinogenesis, as evidenced in basal keratinocyte as decreased (γH2AX-
labeled) DNA-damage, decreased (Illumina HiSeq) levels of Hras mutations, and decreased cuta-
neous tumors. P450 enzyme expression levels within LC and mass spectrometric analysis of LC
cultures implicated their preferential metabolism of the polyaromatic hydrocarbon (PAH) DMBA to
more mutagenic, rather than detoxified, intermediates. Since trafficking of exogenous PAH within
LC is largely unknown, we sought to employ strategies of two-photon confocal microscopy to visu-
alize and quantify uptake, localization, and efflux of DMBA. Following DMBA exposure, time-lapse
live cell imaging revealed the accumulation of DMBA in discreet intracellular foci within the murine
LC line, XS106, as well as in ex vivo LC. Foci were apparent in 50.8% of XS106 cells within 5 min-
utes of DMBA exposure. After 20 minutes, 93.9% of XS106 cells and 85.7% of ex vivo LC con-
tained detectable foci, with intensity increasing linearly. Following 1hr DMBA exposure, diffuse
cytoplasmic fluorescence and bright discreet foci were apparent within LC, with relative exclusion
of DMBA from the nucleus. Upon removal of DMBA, total cellular fluorescence decreased by 77.4%
within the first hour, and the total area occupied by DMBA foci decreased by 94.8%, however rare
foci persisted for >24hr in ex vivo LC. We also investigated the potential for monitoring PAH metab-
olism by coupling two-photon confocal microcsopy and spectral unmixing. Emission spectra of
DMBA and DMBA-t-3,4-diol were collected and used as standards. When these compounds were
applied to XS106, linear unmixing software (Zen) was able to correctly distinguish the metabolite
from the parent compound. These strategies hold promise for further elucidation of how an intraep-
ithelial dendritic cell population such as LC handle exogenous PAHs and provide insight into mech-
anisms of cooperative carcinogenesis.
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Immunological control of mouse papillomavirus (MusPV) infection
JP Sundberg,1 J Joh,2 CS Potter,1 KA Silva,1 V Kennedy,1 A Ingle,3 S Ghim2 and AB Jenson2 1
Research and Development, The Jackson Laboratory, Bar Harbor, ME, 2 James Graham Brown
Cancer Center, University of Louisville, Louisville, KY and 3 Department of Laboratory Animal
Medicine, Tata Memorial Centre, ACTREC, Khargahr, Navi Mumbai, India
The Laboratory mouse papillomavirus (MusPV) naturally infects NMRI-Foxn1nu/Foxn1nu (nude) T
cell deficient mice and S/RV/Cri-ba/ba (bare) immunocompetent mice but not immunocompete-
tent C57BL/6J wild type mice. B6 congenic mice with T cell (Foxn1nu) or T and B cell (Prkdcscid
or Rag1tm1Mom) deficiencies developed productive papillomas on their muzzle and tail skin but
locally invasive, poorly differentiated carcinomas on their dorsal lumbar skin. Mice with only B
cell deficiencies (Ighmtm1Cgn) were not infected. T cell mutations on different inbred strain back-
grounds indicated a strain specific susceptibility in addition to the immunodeficiency. Gene array
studies revealed massive, significant transcriptome changes between the benign tail papillomas
and invasive dorsal skin carcinomas as well as between the control tail and dorsal skin. These results
indicate that there are major strain differences in papillomavirus susceptibility making this a poten-
tially useful model to determine the underlying genetic basis for these responses.
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Regulation of UVB-induced skin cancer by Fyn and Srcasm
X Yang,1 H Nishida,2,1 C Marshall,1 T Dentchev1 and J Seykora1 1 Dermatology, U Penn,
Philadelphia, PA and 2 Rohto, Kyoto, Japan
Cutaneous squamous cell carcinoma (cSCC), the second most common human cancer, is associ-
ated with cumulative UV exposure. Studies show that human actinic keratoses and cSCCs demon-
strate increased activity of Src kinases, in particular, Fyn, and decreased levels of Srcasm, a nega-
tive regulator of Src kinases. Our prior data show that increased Fyn activity lowers levels of p53,
p21, and Notch 1 in keratinocytes which may make them more susceptible to UVB-induced car-
cinogenesis. Herein, we asked if increased Fyn activity would enhance the susceptibility of skin to
UVB-induced neoplasia. We also asked if Srcasm levels would be inversely related to UVB-induced
neoplasia. K14-Fyn Y528F mice were exposed to a single UVB dose of 1200mJ/cm2 and developed
prominent epidermal hyperplasia and activation of the DNA damage response indicated by promi-
nent phospho-H2AX immunohistochemical staining. K14-Fyn Y528F;K14-Srcasm mice and K14-
Srcasm mice lacked these findings and were indistinguishable from controls. In a chronic UV model
which induces cSCC formation in control mice at 25 weeks, K14-Fyn Y528F mice developed mul-
tiple cSCCs by 7-10 weeks and Srcasm null mice developed cSCCs starting at 12 weeks. In the
chronic UV model, K14-Fyn Y528F mice and Srcasm null mice also develop flat, scaly lesions that
histologically demonstrate hyperplasia, keratinocyte atypia, and parakeratotic scale similar to that
seen in human AKs. Controls lacked the scaly lesions and developed mild epidermal hyperplasia.
Immnunohistochemical analysis showed that these scaly lesions demonstrated keratinocyte hyper-
proliferation and activation of endogenous SFKs. recapitulating what is seen in human actinic ker-
atoses (N=17). Western blot analysis of skin from Srcasm null mice demonstrates decreased levels
of p53 and p21 in keratinocytes. In summary, the data show that increased Fyn activity and decreased
Srcasm levels enhance the susceptibility of murine skin to UVB-induced neoplasia and that mod-
ulation of p53 and p21 is mechanistically relevant.
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Evidence for a napdh oxidase-stat5 pathway in human melanoma
JL Arbiser,1,2 MY Bonner,1 R Cerulli,3 S Liu3 and DA Frank3 1 Dermatology, Emory School of
Medicine, Atlanta, GA, 2 Dermatology, VAMC Decatur Ga, Atlanta, GA and 3 Medical
Oncology, Dana-Farber Cancer Institute, Boston, MA
In the age of targeted therapy, interferon alpha is still the mainstay for high risk melanoma. Large
studies demonstrate that despite optimal interferon therapy, morbidity is high and benefit is small.
We have demonstrated elevated NADPH oxidase in melanoma and hypothesize that elevated reac-
tive oxygen could contribute to interferon resistance. In addition, the stat5 transcription factor has
been shown to mediate interferon resistance in melanoma. We synthesized NADPH oxidase inhibitors
based upon the pharmacophore of gentian violet, which we have previously demonstrated to be an
NADPH oxidase inhibitor. Four compounds demonstrated potent dose dependent reduction in stat5
mediated transcription without concomitant changes in stat3 mediated transcription. The prolifer-
ation of stat5 dependent leukemia cell lines was potently inhibited by these compounds. One of
these compounds, gentian violet is already approved for human use, allowing us to test proof of
principle in humans. A 92 year old patient with multiple comorbidities presented with 3 inopera-
ble melanoma metastases on his scalp. After debulking, the patient was treated with gentian violet
and imiquimod to the tumor base. The patient has been free of recurrence as of the writing of this
abstract (11 months). Our data suggests that an NADPH oxidase-stat5 pathway plays a role in
melanoma pathogenesis in humans, and that systemic NADPH oxidase blockade might augment
immunotherapy and chemotherapy in melanoma.
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Gene-gene interactions between nucleotide excision repair RPA3 with XPC and ERCC1 are
associated with risk of nonmelanoma skin cancer
L Wheless,1 E Kistner-Griffin,1 TJ Jorgensen,2 Y Berthier-Schaad,3,4 B Kessing,7 J Hoffman-Bolton,3
YY Shugart,5 W Kao,3 PT Strickland,3 L Francis,1 RM Alani,6 MW Smith7 and AJ Alberg1 1 Medical
University of South Carolina, Charleston, SC, 2 Georgetown, Washington, DC, 3 Johns
Hopkins, Baltimore, MD, 4 NCI-Frederick, Frederick, MD, 5 NIMH, Bethesda, MD, 6 Boston
University, Boston, MA and 7 SAIC-Frederick, Inc, Frederick, MD
Nucleotide excision repair (NER) is a complex pathway involving roughly 30 genes that is respon-
sible for repair of ultraviolet-induced DNA lesions and is a critical safeguard against nonmelanoma
skin cancer (NMSC). In a matched case-control study, minor allele frequencies of 188 single nucleotide
polymorphisms (SNPs) in 28 NER genes were compared between 900 NMSC cases and 900 can-
cer-free controls. An exhaustive search of all 2-SNP combinations was conducted using both logis-
tic regression and multifactor dimensionality reduction, testing each for its association with NMSC.
Conditional logistic regression was then used to calculate odds ratios (OR) and 95% confidence
intervals (CIs), adjusting for the first three principle components of genetic heterogeneity. Three inter-
actions were associated with NMSC at p < 0.0005: (1) RPA3 rs11974817, XPC rs1350344 (p=7.9x10-
5), (2) RPA3 rs7780564, ERCC1 rs3212948 (p = 0.0003), (3) and RPA3 rs7780564, ERCC1 rs3212986
(p = 0.0004). The strongest risks were observed for RPA3-XPC interaction 1: compared to the AA-
GG genotype, individuals with the GG-GG genotype had nearly triple the risk of NMSC (OR 2.93,
95% CI 1.76-4.80), with OR > 2.0 for the AA-AG, AA-AA, and GG-AG. In contrast, 6 of the 8 geno-
types with any minor alleles for RPA3-ERCC1 interactions 2 and 3 had OR < 1.0 for risk of NMSC
compared to the genotype with 2 major alleles for both SNPs, with the AC-GG genotype for inter-
action 2 having OR 0.51 compared to the CC-GG genotype. Molecular evidence supports a direct
interaction of RPA3 with ERCC1 at the protein level. Additional studies are necessary to clarify the
role of these interactions in NMSC pathogenesis.
S26 Journal of Investigative Dermatology (2012), Volume 132
SID12_Abstracts-2  2/21/12  8:10 AM  Page S26
Carcinogenesis, Growth Factors, and Cancer Genetics | ABSTRACTS
156
Characterization of a human Merkel cell carcinoma cell line
K Liang,1 L Shao,2 S Ye,3 C Gurley,1 W Feng,2 BC Stack Jr,4 D Davis1 and L Gao1 1 Dept. of
Dermatology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, 2 Dept.
of Pharmaceutical Sciences, UAMS, Little Rock, AR, 3 Dept. of Internal Medicine, UAMS, Little
Rock, AR and 4 Dept. of Otolaryngology-Head and Neck Surgery, UAMS, Little Rock, AR
Merkel cell carcinoma (MCC) is an aggressive skin cancer with rising incidence, especially in AIDS
and organ transplant patients. MCC is often metastatic at presentation, with a 33% mortality rate,
which is far exceeding that of melanoma. Unlike other cancers, common tumor suppressor genes
and oncogenes known to govern carcinogenesis are less frequently mutated in MCC. Moreover,
growth factor pathways, such as MAP kinase and Akt pathways, are not constitutively activated in
MCC. While Merkel cell virus (MCV) has been detected in MCCs, the pathogenesis of MCC remains
a captivating question. To characterize the cellular and molecular mechanisms of MCC carcino-
genesis we have established a primary human MCC cell line (MCC-LG) from a MCC patient with
lymph node metastasis. MCC-LG cells display in clusters on human fibroblast feeder layer. By
immunofluorecent and RT-PCR analysis, they express both epithelial and neuronal marker, such as
cytokeratin 18, 19, 20, synaptophysin, neurospecific enolase. By PCR and direct DNA sequencing
analysis, the MCC-LG cell line is negative for MCV. Under electron microscopy, the cells contain
characteristic large nuclei, prominent nucleoli as well as “dense-core” granules in the cytoplasm,
as previously reported. In contrast to small cell lung cancer cell line CRL-2049, a neuroendocrine
tumor that resembles MCC histologically, re-stimulation of MCC-LG cells with fetal bovine serum
after 12-hour serum starvation increases apoptosis as measured by Annexin-V flow-cytometry. In
addition, MCC-LG cells have lower autophagosome formation rate and mTOR activity as deter-
mined by the level of autophagy marker LC3-II, phosphorylation of p70-S6kinase and 4EBP1, respec-
tively, as compared with CRL-2049. In summary, the MCC-LG cell line provides a useful tool in
studying mechanisms of MCC pathogenesis.
158
Exploiting deregulated apoptotic signaling as a therapeutic strategy for Merkel cell carcinoma
ME Verhaegen,1 CK Bichakjian,1 T Vozheiko,1 J Weick,1 M Voutsalath,1 TM Johnson1 and
AA Dlugosz1,2 1 Dermatology, University of Michigan, Ann Arbor, MI and 2 Cell and
Developmental Biology, University of Michigan, Ann Arbor, MI
Merkel cell carcinoma (MCC) is a rare but potentially aggressive neuroendocrine skin cancer that
has a poor prognosis at advanced stages. MCC frequently contains DNA sequences from a Merkel
cell polyomavirus (MCV) which has been implicated in tumor initiation and progression, but the
endogenous signaling molecules involved in MCC tumorigenesis have not yet been defined. Pre-
vious studies have documented elevated levels of the anti-apoptotic molecule Bcl-2 in MCC, how-
ever, a clinical trial using Bcl-2 antisense showed no objective responses, suggesting that addi-
tional molecules regulating apoptosis may be contributing to MCC chemoresistance. Here we report
that immunoblot analysis showed ~90% of MCCs (N=9) expressed high levels of not only Bcl-2,
but also Bcl-xL, and Mcl-1 family members, with >70% also exhibiting upregulation of the caspase
inhibitors survivin and XIAP, identifying multiple defects in apoptotic signaling pathways in MCC.
For pharmacological studies, we established and characterized 11 novel MCC lines. All lines grow
in suspension (as shown for other MCC lines), express the Merkel cell marker ATOH1 and neu-
roendocrine marker chromogranin A, and 5 are tumorigenic in nude mice. Since conventional DNA
damaging agents such as carboplatin produced minimal responses in our cell lines (<15% cell death;
50μM), we focused on the pan Bcl-2 family inhibitor TW-37 and a multi-IAP antagonist AT-406, tar-
geted small molecules designed to overcome apoptotic blockades. Single agent studies with both
TW-37 (5μM) and AT-406 (10μM) induced a >50% reduction in viable cell numbers in multiple
lines with nominal effects on normal melanocytes, fibroblasts and keratinocytes. Additionally,
combination of these agents with carboplatin resulted in enhanced cytotoxic effects. Our results
identify multiple alterations in apoptotic signaling and suggest that targeting these pathways can be
exploited for therapeutic purposes in MCC.
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HB-EGF directly promotes epithelial-mesenchymal transition and invasiveness in human ker-
atinocytes
SW Stoll,1 L Rittié1 and JT Elder1,2 1 Dermatology, University of Michigan, Ann Arbor, MI and
2 Ann Arbor VA Hospital, Ann Arbor, MI
We have previously shown that the EGFR ligands AREG and HB-EGF have distinct context-depend-
ent functions in human keratinocytes (KC), with AREG being particularly important for proliferation,
whereas overexpression of HB-EGF leads to pronounced increases in KC motility and profound mor-
phological changes. To explore whether the phenotypic and behavioral changes of HB-EGF expres-
sion in KC coincide with an increased invasive capacity, we performed Matrigel invasion assays.
HB-EGF overexpressing KC showed a strongly increased invasiveness relative to control KC, com-
parable to the human fibrosarcoma cell line HT1080. The motogenic effects of HB-EGF are directly
due to shed HB-EGF, as removal of His-tagged HB-EGF from KC conditioned medium by nickel
chromatography completely abolishes its effect on cellular motility. Consistent with the induced
morphological changes characteristic of cells undergoing epithelial-mesenchymal transition (EMT),
HB-EGF significantly decreased mRNA expression of several epithelial markers including keratins
1, 5, 10, and 14 (62 to 98%, p<0.05), while increasing expression of markers of cellular motility
including SNAI1, ZEB1, COX-2, MMP1 and MMP10. Suggestive of a trade-off between KC motil-
ity and proliferation, overexpression of HB-EGF strongly reduced KC growth in six-day growth assays
by more than 90% (n= 6, p<0.001). Indicative of in vivo relevance, we showed by laser capture
microdissection and PCR that HB-EGF mRNA was strongly induced (274-fold, n=6) in regenerat-
ing epidermis one week after CO2 laser-induced partial thickness wounding of human skin, remain-
ing elevated for four weeks. Together, our data strongly implicate HB-EGF as a direct mediator of
the molecular mechanisms that control EMT and invasiveness.
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Evidence suggesting that cosmetic therapies may prevent non-melanoma skin cancer
DF Spandau, DA Lewis, MA Carozza, A Somani and JB Travers Dermatology, Indiana University
School of Medicine, Indianapolis, IN
The incidence of non-melanoma skin cancer (NMSC) increases dramatically in geriatric individu-
als, such that it is a common affliction in people over 60 years of age. Our laboratories have demon-
strated that the increased susceptibility of elderly patients to develop NMSC is in part due to the
failure of geriatric skin to respond appropriately to UVB irradiation. This inappropriate UVB response
represents a failure of the protective measures found in young skin which prevents the propagation
of UVB-induced mutations in proliferating basal layer keratinocytes. We have previously shown that
the protective appropriate UVB response in young adult skin is mediated by insulin-like growth
factor-1 (IGF-1) secreted from dermal fibroblasts. In dermis of geriatric skin, an increasing propor-
tion of senescent fibroblasts results in a silencing of dermal IGF-1 production and the resulting inap-
propriate UVB response, defined as basal keratinocytes proliferating with UVB-induced DNA dam-
age. We hypothesized that commonly used therapeutic stromal wounding therapies can reduce the
percentage of senescent fibroblasts and consequently prevent the formation of keratinocytes pro-
liferating with DNA mutations following acute genotoxic (UVB) stress. Geriatric volunteers were
treated with fractionated laser resurfacing (FLR) therapy on either sun-protected (upper buttocks) or
chronically sun-exposed (dorsal forearm) skin. At three months following FLR therapy, we observed
a decrease in the occurrence of senescent fibroblasts in geriatric dermis, an increase the dermal
expression of IGF-1, and a restoration of the appropriate UVB response in geriatric keratinocytes.
These responses to FLR were equal to the effects seen previously using dermabrasion, and FLR was
effective in both sun-protected and sun-exposed skin. Preliminary data indicate that the protective
effect of FLR can last for at least two years. The ability of FLR treatment to protect against the occur-
rence of UVB-damaged proliferating keratinocytes indicates the potential of FLR to reduce or pre-
vent aging-associated NMSC.
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Using a gene signature to predict metastases in melanoma patients
C Carson,2 B Omolo,8 H Chu,1 Y Zhou,6 P Tompkins,6 D Simpson,4,5 C Fan,6 A Sarasin,7 P Dessen,7
J Ibrahim,3,5,6 W Kaufmann4,5,6 and N Thomas2,5,6 1 Division of Biostatistics,, University of
Minnesota, Minneapolis, MN, 2 Dermatology, University of North Carolina Chapel Hill,
Chapel Hill, NC, 3 Biostatistics, University of North Carolina Chapel Hill, Chapel Hill, NC, 4
Pathology and Laboratory Medicine, University of North Carolina Chapel Hill, Chapel Hill,
NC, 5 Center for Environmental Health and Susceptibility, University of North Carolina
Chapel Hill, Chapel Hill, NC, 6 Lineberger Comprehensive Cancer Center, University of North
Carolina Chapel Hill, Chapel Hill, NC, 7 Institut Gustave Roussy, Villejuif, France and 8
Division of Mathematics and Computer Science, University of South Carolina Upstate,
Spartanburg, SC
A small percentage of melanoma cell lines are found to be sensitive to ionizing radiation. Using
microarrays from 35 melanoma cell lines, we have determined a gene signature that predicts the
susceptibility of these cells lines to ionizing radiation. This gene list also predicts overall survival in
breast cancer patients and predicts the occurrence of metastases in melanoma patients. Melanoma
cell lines and normal human melanocytes were assayed for p53-dependent G1 checkpoint response
to ionizing radiation-induced DNA damage. Sixty-six percent of melanoma cell lines displayed a
defective G1 checkpoint. Checkpoint function was correlated with sensitivity to ionizing radiation
with checkpoint-defective lines being radio-resistant. Microarray analysis identified 316 probes
whose expression was correlated with G1 checkpoint function in melanoma lines (P<0.007) includ-
ing p53 transactivation targets CDKN1A, DDB2 and RRM2B. The 316 probe list predicted G1 check-
point function of the melanoma lines with 86% accuracy using a binary analysis and 91% accu-
racy using a continuous analysis. When applied to microarray data from primary cancers, the 316
probe list was prognostic of overall survival among breast cancer patients and four year distant metas-
tases-free survival among melanoma patients. Thus, p53 function, radio-sensitivity and metastatic
spread may be estimated in melanomas from a signature of gene expression.
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Defective cell cycle arrest and DNA repair in Merkel cell carcinogenesis
SK Demetriou,1,2 K Ona-Vu,1,2 EM Sullivan,1,2 TK Dong,1,2 S Hsu1,2 and DH Oh1,2 1 Department
of Dermatology, University of California, San Francisco, San Francisco, CA and 2 Dermatology
Research Unit, VA Medical Center, San Francisco, CA
The pathways by which Merkel cell polyomavirus (MCV) infection contributes to the formation of
Merkel cell carcinomas are important for understanding the pathogenesis of these cancers. We
hypothesized that MCV T antigen suppresses normal responses to ultraviolet radiation (UV)-induced
DNA damage. An MCV-infected cell line exhibited UV hypersensitivity, DNA repair defects and
G1 cell cycle arrest failure following UVR, as well as reduced levels of the DNA damage recogni-
tion protein, XPC. When ectopically expressed in an uninfected Merkel cell carcinoma cell line,
mutant but not wild-type T antigen resulted in loss of DNA repair and reductions in XPC, p53 and
p21 levels, whereas both wild-type and mutant T antigen inhibited cell cycle arrest following UV.
Similarly, only mutant T antigen in normal fibroblasts inhibited DNA repair and XPC expression,
while both mutant and wild-type T antigens produced cell cycle dysregulation. Expression of the
wild-type large T antigen isoform but not the small T antigen isoform inhibited cell cycle arrest fol-
lowing UV, and neither wild-type large T nor small T antigens affected DNA repair, suggesting that
large T antigen generates cell cycle defects, and when mutated may also impair DNA repair. These
results indicate that T antigen expression by MCV can inhibit key responses to UVR-induced DNA
damage and suggest that progressive MCV-mediated abrogation of genomic stability may be involved
in Merkel cell carcinogenesis.
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Early Langerhans cell-specific responses to exogenous polyaromatic hydrocarbon exposure
R Filler, J Lewis and M Girardi Yale School of Medicine, New Haven, CT
Langerhans cell (LC)-deficient mice are protected from chemical carcinogenesis initiated by the pol-
yaromatic hydrocarbon (PAH) DMBA, and from DMBA-induced DNA damage. Since regulation of
apoptosis may also contribute to carcinogenesis, we examined LC influence on DMBA-induced ker-
atinocyte (KC) apoptosis by cleaved caspase 3 (CC3) staining and found LC-intact mice had 2x CC3+
KC 24hr after exposure. Only 0.02% of LC co-stained with CC3 and 0.97% with γH2AX, revealing
LC resistance to DMBA-induced damage. In response to PAH exposure, liver and epithelial cells
activate “xenobiotic response” genes including Cyp1a1, Cyp1b1, and Epxh1; however, the LC
response to PAH is largely unknown. We previously demonstrated preferential up-regulation of
Cyp1b1 by LC and Cyp1a1 by KC following DMBA exposure, and have now quantified expression
of Epxh1 and other genes including CD207, CD80 and IDO1. DMBA exposure led to only modest
increases in LC expression of Epxh1, but marked elevation in KC. These data define a unique PAH
response pattern for LC. To confirm the importance of the LC PAH-metabolizing enzyme profile in
carcinogenesis, a LC-specific enzyme-deficient variant is needed. Therefore, we sought to use fetal
LC precursors to repopulate LC-deficient mice. Such precursors are hypothesized to exist in both
embryonic yolk sac (YS) and fetal liver (FL), and we have tested each for the ability to repopulate
LC-deficient mice. Cell suspensions from E10.5 YS or E12.5 FL were injected into newborn LC-defi-
cient recipients. Flow cytometric analysis of epidermal cells from 3wk old FL recipients showed LC
repopulation at 33% control levels. YS recipients had up to 28% reconstitution at 3.5wks and 50%
at 8wks. These results suggest this approach holds promise for development of a system for testing
a variety of LC-specific variants, further defining the role of LC in carcinogenesis and other aspects
of skin immunity.
163
Forward genetic screen to identify genes that confer drug resistance to BRAF-inhibitors in
melanoma
J Choi,1 N Rahman,1 S Landrette2 and T Xu2 1 Dermatology, Yale School of Medicine, New
Haven, CT and 2 Genetics, Yale School of Medicine, New Haven, CT
Despite the initially promising results of BRAF inhibitors in clinical trials, pharmacological cure of
melanomas is limited by the development of drug resistance and the subsequent high relapse rate
with progressive disease. To systematically identify the genes and pathways that confer drug resist-
ance in melanoma, we utilized a forward genetic screen using transposon insertional mutagenesis
(TIM) as a means of systematically interrogating the cancer genome for genes that can mediate resist-
ance to targeted BRAF therapy. We developed a system employing the non-autonomous PiggyBac
transposons, which can insert efficiently and randomly into mammalian cells across the genome.
We engineered mutagenic elements within the transposon including cassettes that can upregulate
or downregulate gene transcription near the insertion sites. Depending on the orientation of the
transposon and the site of insertion, the mutagenic transposon can therefore confer gain-of-func-
tion or loss-of-function properties. Furthermore, the utilization of the tet operon within the trans-
poson together with the doxycycline-sensitive transcriptional repressor, TetR-KRAB, enables rapid
identification of transposon-dependent drug-resistant mutants. Common insertion site analysis derived
from 100 transposon-dependent drug resistant clones have led to the identification of two genes
known to confer resistance to BRAF inhibitors, CRAF and BRAF. Underscoring the importance of
these findings, spontaneous drug resistant mutant cell lines are sensitive to combined BRAF and
MEK inhibition. Insertions in BRAF occurred all in intron 8, permitting the overexpression of the N-
terminal truncated BRAF, which is uniquely capable of resisting PLX4032 in cells and has been
found as a common mechanism of drug resistance. We therefore propose the use of TIM as a rapid
means of identifying genes, splice variants, and pathways important for tumor drug resistance.
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Interferon-γ renders myeloid-derived suppressor cells (MDSC) with the potent immunosup-
pressive activity via inducing expression of DC-HIL and inducible nitric oxide synthase (iNOS)
J Chung, K Tamura, PD Cruz and K Ariizumi Dermatology, UT Southwestern, Dallas, TX
Despite the critical role of MDSC in tumor progression, molecular mechanisms through which MDSC
become immunosuppressive and suppress T cell responses remain unclear. Having shown DC-HIL
receptor to be responsible for the suppressive activity of MDSC induced in mice with melanoma,
we studied the mechanisms for induction of DC-HIL+ MDSC and DC-HIL-mediated suppression.
To identify triggers of DC-HIL expression, MDSC (harvested from day 5 culture of bone marrow cells
with GM-CSF/IL-4) were treated with 10 different soluble factors and assayed for DC-HIL expres-
sion and the T cell-suppressive activity. GM-CSF/IL-4 alone generated 80% MDSC, all of which were
DC-HILneg and not suppressive. Among factors tested, IFNγ or IL-1β induced significant levels of
DC-HIL+ MDSC (20-40%), and the combination amplified it (60%). Such DC-HIL+ MDSC were the
most potent suppressors among others generated. To study mechanisms of the suppressor function,
we examined effect of different inhibitors on ability of MDSC (from mice with melanoma) to inhibit
T cell proliferation induced by gp100 Ag. Among 13 inhibitors to coinhibitory receptors, cytokines
and soluble inhibitory mediators (ROS, urea, NO), anti-IFNγ Ab and an iNOS inhibitor abolished
the suppressor activity completely and independently. Having shown anti-DC-HIL Ab blocks the
function completely; and DC-HIL has the intracellular tyrosine (Tyr)-based signal motif (ITAM), we
posited that DC-HIL transduces Tyr-signals after binding to the ligand, leading to IFNγ and iNOS
expression. We assayed Tyr phosphorylation on DC-HIL and expression of the 2 mediators after
crosslinking DC-HIL on MDSC by Ab (a surrogate ligand). Crosslinking induced a rapid Tyr phos-
phorylation on the ITAM and marked upregulation of IFN-γ mRNA/protein (20-50-fold greater than
control); iNOS mRNA and NO (5-10-fold). Thus, the critical role of IFNγ in activating MDSC and
mediating the suppressor activity suggests that inflammation promotes melanoma progression via
DC-HIL+ MDSC.
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Shh-mediated Akt1 activation promotes survival of Ptch1 +/– keratinocytes and drives growth
of basal cell carcinomas (BCCs)
AL Kim,1 JH Back,1 Y Zhu,1 X Tang,1 M Athar2 and DR Bickers1 1 Dermatology, Columbia
University, New York, NY and 2 University of Alabama at Birmingham, Birmingham, AL
Aberrant sonic hedgehog (Shh) signaling drives BCC pathogenesis in part by enhancing expression
of transcription factors such as Gli1 and Gli2; however, preclinical studies and clinical trials sug-
gest involvement of additional pathway(s). Akt1, a protein kinase that is essential for cell growth
and proliferation, phosphorylates numerous proteins involved in cell cycle progression and tumori-
genesis including mammalian target of rapamycin (mTOR), which in turn phosphorylates S473 of
Akt1, facilitating its full activation. In both human and UVB-induced murine BCCs, S473 Akt1 phos-
phorylation occurs in tumor cells suggesting cooperative interaction between Akt1 and Shh. The
connection between phosphorylated Akt1 and Shh signaling in the pathogenesis of BCCs is unclear.
Here, we show that co-activation of the Akt1 and Shh pathways via constitutive over-expression of
myristoylated Akt1 and the GLI2 activator Gli2N in keratinocytes increased cell proliferation,
whereas combined chemical inhibition of Akt and Shh decreased the growth of UVB-induced
BCCs in Ptch1 +/–/SKH-1 mice. Moreover, haplodeficiency of Akt1 in these mice completely blocked
growth of microscopic BCCs and reduced UVB-induced BCCs, confirming Akt1’s importance for
BCC growth. SOX9 is a Gli1 regulated transcription factor that is overexpressed in BCCs and binds
directly to the mTOR promoter in vivo. Genetic ablation of SOX9 diminished mTOR expression,
thereby blocking phosphorylation of mTOR substrates including p7056K and 4E-BP1 as well as
S473 Akt1 phosphorylation confirming that Shh regulates Akt1. Indeed Akt1 S473 phosphorylation
was enhanced in primary keratinocytes isolated from newborn Ptch1 +/–/SKH-1 mice as compared
to Ptch1 +/+ mice. Furthermore, Gli2N expression in keratinocytes blocked UV-induced apopto-
sis via SOX9/mTOR-mediated Akt1 activation. Our data confirm cross-talk between Akt1 and Shh
pathways, showing that Shh-mediated Akt1 activation via mTOR fosters cell survival and growth of
BCCs.
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Circadian clock controlled sensitivity to UVB-induced DNA damage in the epidermis
M Geyfman,1 V Kumar,2,3 Q Liu,4 R Ruiz,1 W Gordon,1 F Espitia,1 E Cam,1 P Smyth,4,5 A Ihler,4
J Takahashi2,3 and B Andersen1,5,6 1 Department of Biological Chemistry, University California
Irvine, Irvine, CA, 2 Department of Neuroscience, University of Texas Southwestern Medical
Center, Dallas, TX, 3 Howard Hughes Medical Institute, University of Texas Southwestern
Medical Center, Dallas, TX, 4 Department of Computer Science, University California Irvine,
Irvine, CA, 5 Institute for Genomics and Bioinformatics, University California Irvine, Irvine, CA
and 6 Department of Medicine, University California Irvine, Irvine, CA
We defined the circadian transcriptome of mouse skin at telogen and anagen stages of the hair cycle.
While the circadian transciptomes of anagen and telogen skin are largely distinct, the former is dom-
inated by genes involved in cell proliferation and metabolism. Correspondingly, cell proliferation
within the interfollicular epidermis and upper part of hair follicles is highly circadian. In the highly
proliferative compartments of the anagen follicles circadian variation of proliferation is less promi-
nent. The circadian variation is epidermal proliferation is controlled by Bmal1 intrinsic to ker-
atinocytes as both global and K14Cre-mediated deletion of Bmal1 obliterates circadian synchronicity
of cell division in the epidermis. Furthermore, Bmal1-dependent circadian expression of oxidative
phosphorylation enzymes and accumulation of ROS is antiphasic to the zenith of epidermal S-phase,
suggesting a role for the circadian clock in the temporal separation of oxidative metabolism and
DNA synthesis in the epidermis, a mechanism that may protect the genome from ROS-mediated
damage. Furthermore, epidermis is more sensitive to UVB-induced DNA damage at night than in
the day; this circadian variation is also Bmal1 dependent. In contrast to mouse epidermis, human
epidermis contains maximum number of keratinocytes in S phase in the late afternoon. The circa-
dian clock, therefore, imposes regulation of epidermal cell proliferation such that human skin is at
a particularly vulnerable stage during times of maximum UV exposure, which could contribute to
the very high incidence skin cancers in humans
167
SMO inhibitor effectiveness in a patient with a SHH locus translocation causing holopros-
encephaly and basal cell carcinomas
N Gomez-Ospina, CD Bangs, K Qu, AL Chang and AE Oro Program in Epithelial Biology,
Stanford University School of Medicine, Stanford, CA
Misregulation of the Hedgehog (Hh) signaling pathway has been implicated in human midline devel-
opmental defects such as holoprosencephaly (HPE) and several forms of cancer including basal
cell carcinomas (BCCs) which contain pathway mutations, and pancreatic/lung cancer that lack
pathway mutations but upregulate the hedgehog ligand. Interestingly, SHH alterations leading to
cancer predisposition have not been reported. Here we describe a novel patient with a balanced
translocation t(7;Y)(q11.21;q36) that displays mild HPE, cutaneous SHH overexpression and innu-
merable invasive BCCs starting at age 9. Whole-genome paired-end sequencing demonstrates that
Y chromosome sequences between the azospermia determining region A and B are juxtaposed
within the SHH regulatory region 140 kb upstream of the SHH transcription start site. The molecu-
lar analysis suggests the HPE derives from SHH haploinsufficiency during development caused by
loss of normal regulatory sequences, and the BCCs come from post-natal ectopic SHH expression
in the skin. Consistent with this finding, SHH RNA and protein levels are increased in the patient’s,
but not control, BCCs. Smo inhibitor treatment dramatically reduces the BCC burden, demonstrat-
ing the effectiveness of Smo inhibitors in the treatment of SHH-expressing tumors.
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Novel L1 and Alu retrotransposon insertions in melanoma related gene loci in NCI-60
melanoma cell lines
J Zampella and KH Burns Johns Hopkins, Baltimore, MD
Long Interspersed Elements (L1 LINE) and Alu Short Interspersed Elements (SINE) are active Trans-
posable Elements (TEs) which comprise a major fraction of our genome. TEs have been implicated
in oncogenesis but their functional roles remain underexplored largely because current methods
are unable to locate these high copy number repeats-a barrier recently overcome. Using a new
genomic method, this study aims to discover TEs in melanoma cell lines. Using transposon inser-
tion profiling microarray (TIP-chip) on genomic DNA from NCI-60 tumor cell lines, vectorette PCR
selectively amplified the 3’ end of TEs to yield unique DNA fragments. These PCR amplicons were
fluorescently labeled and hybridized to a custom genomic tiling microarray. Contiguous positive
probes were detected as peaks. Data analysis included filtering peaks for ‘true’ insertions and
annotating their locations with respect to known TEs and genes. This yields 224 unique candidate
L1 insertions (100 known and 124 novel) and 1,661 candidate Alu insertions (794 known and 867
novel) across 8 NCI-60 melanoma cell lines. Of the L1 insertions, 175 are present in more than one
cell line. The number of unique insertions per cell line ranges from 5-31. There were 184 cancer
genes within 5kb of predicted L1 insertion intervals and 23 putative L1s were within 500 bases of
an exon. Genes with published relationships to melanoma include XIAP, BAGE and SP1. 1,057 of
the 1,661 candidate Alu insertions were present in multiple cell lines and unique Alu insertions per
cell line ranged from 12-166. 854 cancer genes were within 5kb of predicted Alu insertions, 60 with
relevance to melanoma including pTEN, BRAF, cKIT and EGF. This is the first study to use a high
through-put method to discover novel TE insertions in melanoma. This study affirms that TIP-chip is
an effective method to discover novel TE insertions. Novel TE insertions in proximity to known can-
cer genes provide specific candidates for studying the functional significance of TEs in melanoma.
On-going work will compare these to insertions in other NCI-60 tumor cell lines.
170
Indian hedgehog protects from malignant progression of skin tumours
P Kakanj,1 G Séquaris,1 D Fehrenschild,1 P Schettina,1 CC Zouboulis2 and C Niemann1 1 Center
for Molecular Medicine Cologne, University of Cologne, Cologne, Germany and 2
Departments of Dermatology, Venerology, Allergology and Immunology, Dessau Medical
Center, Dessau, Germany
The Hedgehog signalling cascade plays essential roles in morphogenesis, maintenance and regen-
eration of the skin epithelium. Mutations in components of the hedgehog pathway often result in
skin abnormalities and tumour formation, e.g. basal cell carcinoma. Out of three mammalian hedge-
hog homologs, Sonic hedgehog (Shh) is the best-characterized hedgehog ligand in the skin and is
required for hair follicle formation and regeneration. Previously, we have shown that Indian hedge-
hog (Ihh) is also expressed by keratinocytes; however, an in-vivo function for Ihh in skin develop-
ment, homeostasis or patho-physiological conditions has not been identified yet. Here we have gen-
erated and analyzed epidermis-specific knock-out mice for Ihh (Ihh-EKO mice) and demonstrate
that proliferation is inhibited in early postnatal skin development upon epidermal depletion of Ihh.
Morphogenesis of the interfollicular epidermis and its appendages were not severely changed, which
is most likely due to the compensatory effect of other hedgehog ligands. Importantly, Ihh controls
important aspects in the process of formation and progression of different types of skin cancer. In
particular, proliferation and sebocyte differentiation were strongly reduced in sebaceous tumours
of Ihh-EKO mice. Proliferation and differentiation were also altered in squamous skin cancer induced
in Ihh-EKO mice. Surprisingly, tumour progression of papilloma into squamous cell carcinoma was
enhanced in Ihh-EKO mice and metastases were detected in lymph nodes and lung. Furthermore,
our data indicate that Ihh is mediating its effects via the transcription factors Gli2 and Gli3. Thus,
our novel results clearly show that Ihh plays a crucial role controlling proliferation and differentia-
tion of keratinocytes and that epidermal depletion of Ihh promotes a malignant phenotype of skin
tumours.
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Transcriptome sequencing in squamous cell carcinoma identifies novel skin malignancy reg-
ulated transcripts
C Lee, A Ungewickell, A Bhaduri, K Qu, D Webster, C Aros, A Mah, M Kretz and PA Khavari
Stanford University, Stanford, CA
Massively parallel cDNA sequencing (RNA-Seq) can characterize all RNA transcripts in cancer tis-
sues to discover new roles for noncoding and novel transcripts. To identify viral elements, gene
fusions, protein coding gene expression patterns, and novel RNA transcripts in squamous cell car-
cinoma (SCC), whole transcriptome sequencing was performed on 3 primary cutaneous SCCs as
well as site- and patient-matched normal skin. Paired-end sequencing was performed on the Illu-
mina Hi-Seq platform with an average depth of 111 million reads per sample. Bioinformatic analy-
sis did not identify either non-human transcripts, such as human papilloma virus (HPV) to support
a viral etiology of SCC or recurrent gene fusions similar to those seen in specific visceral malig-
nancies. Gene set enrichment analysis of differentially expressed protein-coding genes identified
enhanced Ras, ERK, and PI3K signaling as well as activation of cell motility genes. Additionally, a
statistical enrichment for down-regulating of Notch signaling pathway components was seen. Altered
expression of 7 annotated long noncoding RNAs (lncRNAs) was also observed in SCC, verified in
9 additional SCCs. SCC transcriptome assembly by multiple algorithms, including Scripture and
Trinity, discovered 11 previously unannotated skin malignancy-regulated transcripts (SMRTs) that
are differentially expressed in SCC. The majority of these new SMRTs were confirmed to be Ras-
regulated in human organotypic neoplasia. SMRTs include 8 predicted long noncoding RNAs (lncR-
NAs) as well as 3 novel transcripts with evolutionary conservation scores that strongly support pro-
tein coding potential. Functional characterization of these new lncRNAs and SMRTs is underway
in Ras-driven organotypic human neoplasia. Our findings characterize the SCC transcriptome, sup-
port recent reports implicating lncRNA dysregulation in cancer, and identify SMRTS as entirely novel
SCC-associated transcripts with a potential role in the pathogenesis of this cancer.
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Topical application of the PAFR agonist carbamoyl PAF or oral administration of the PPARγ
agonist Rosiglitazone suppresses chemical carcinogenesis and chronic PMA-induced inflam-
mation
RL Konger,1,2 RP Sahu,1,2 S DaSilva,2,1 JB Travers2,1 and S Rezania1 1 Pathology & Laboratory
Medicine, Indiana University School of Medicine, Indianapolis, IN and 2 Dermatology,
Indiana University School of Medicine, Indianapolis, IN
Diverse oxidative stressors, such as ultraviolet light and tert-butylhydroperoxide (TBH), induce the
formation of oxidized glycerophosphocholines (ox-GPCs) from membrane phospholipids. In turn,
ox-GPC’s exhibit potent ligand activity for both the platelet activating factor receptor (PAFR) and
the peroxisome proliferator activated receptor gamma (PPARγ). Recent studies have shown that mice
lacking the PAFR or epidermal PPARγ (Pparg-/-epi) exhibit increased sensitivity to chemical car-
cinogenesis and Pparg-/-epi mice exhibit augmented photocarcinogenesis. Increased carcinogene-
sis in both knockout models were accompanied by a significant increase in chronic inflammation.
We now show that topical administration of the non-hydrolyzable PAFR agonist, carbamoyl PAF
(CPAF; 30 nmole) applied immediately after DMBA or PMA treatment, or oral administration of the
PPARγ agonist rosiglitazone (≈ 7.7 mg/kg/day), both act to significantly suppress tumor burden and
tumor size following a DMBA/PMA chemical carcinogenesis protocol in SKH-1 mice. CPAF sup-
pressed tumorigenesis by approximately 50% while rosiglitazone suppressed tumorigenesis by
approximately 70% relative to mice treated with vehicle alone. PPARγ activation is known to sup-
press inflammation in models of steatohepatitis and metabolic syndrome. Thus, it is not surprising
that rosiglitazone significantly suppressed PMA-induced skin thickness following 6 treatments over
3 weeks. In contrast, CPAF treatment, at a dose which significantly induces a transient acute edema
response in mouse skin after a single application, paradoxically suppressed the increase in skin
thickness induced by repeated PMA applications. Thus, ox-GPCs and their respective cellular recep-
tor targets may have evolved as a protective response to the pro-inflammatory and pro-tumorigenic
activity of repeated exposures to environmental oxidants.
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Aldehyde dehydrogenase activity is cancer stem cell marker in human cutaneous squamous
cell carcinoma
M Yasuda,1,2 J Chen,1,2 SE Robinson,3 M Fujita1,2 and DR Roop1,2 1 Department of Dermatology,
University of Colorado Denver, Aurora, CO, 2 Charles C. Gates Regenerative Medicine and
Stem Cell Biology Program, University of Colorado Denver, Aurora, CO and 3 Division of
Medical Oncology, University of Colorado Denver, Aurora, CO
The concept of cancer stem cells (CSCs) is well accepted for solid tumors that arise in wide variety
of organs. In the skin, most published reports have focused on the identification of CSCs in malig-
nant melanoma, with less attention given to cutaneous squamous cell carcinoma (cSCC). Aldehyde
dehydrogenase (ALDH) is an intracellular enzyme that is involved in converting retinol to retinoic
acid. High ALDH activity has been detected in CSCs populations of numerous solid tumors, includ-
ing head and neck SCC. Therefore, we wanted to determine whether high ALDH activity was a
marker of CSCs in cSCC. To date, we have analyzed 4 primary cSCCs, 3 xenografted cSCCs that we
have established as direct patient tumor xenografts. On average, 0.67% of the cells in primary cSCC,
and 0.88% of the cells in xenografted cSCC express high levels of ALDH. To compare the tumor
initiating capacity of cells expressing low and high levels of ALDH, we injected 5,000 ALDH+ and
5,000 ALDH- cells into graft sites that had been humanized by implanting Gelfoam® with human
fibroblasts and Matrigel® into NOD/SCID mice. Only the ALDH+ cells were able to initiate tumor
formation. These tumors could be serially passaged and morphologically, they recapitulated the
parental tumor histology and were heterogenous, i.e., comprised of both ALDH+ and ALDH- cells.
Immunofluorescence analysis of these tumors revealed that ALDH+ cells did not co-localize with
Ki67, which is consistent with their quiescent nature. Taken together, our results suggest that high
ALDH activity is a marker of CSCs in cSCC.
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Transcriptome sequencing in Sézary Syndrome identifies novel Sézary cell-associated tran-
scripts
C Lee, A Ungewickell, A Bhaduri, K Qu, D Webster, R Armstrong, W Weng, C Aros, A Mah,
M Kretz, YH Kim and PA Khavari Stanford University, Stanford, CA
Sézary syndrome (SS) is an aggressive cutaneous T-cell lymphoma of unknown etiology in which
malignant cells circulate in the peripheral blood. To identify gene expression patterns associated
with this lymphoma and address whether viral elements and gene fusions feature prominently in
this disease, we employed massively parallel cDNA sequencing (RNA-Seq). Flow cytometry was
used to obtain matched pure populations of malignant versus non-malignant CD4+ T-cells from the
blood of 3 SS patients for whole transcriptome sequencing. Paired-end sequencing was performed
on the Illumina Hi-Seq platform to an average depth of 112 million reads per sample. Bioinformatic
analysis did not identify either non-human transcripts to support a viral etiology of SS or recurrent
gene fusions. Gene set enrichment analysis of differentially expressed protein-coding genes identi-
fied dysregulation of PI3K/Akt, TGFβ, and NF-κB pathways as well as T-cell receptor signaling. SS
transcriptome assembly by multiple algorithms identified 13 differentially expressed new, previ-
ously unannotated transcripts, termed Sézary cell-associated transcripts (SeCATs). SeCATs include
12 predicted long non-coding RNAs (lncRNAs) as well as a highly conserved novel transcript with
strong protein coding potential. Our findings represent the first application of RNA-Seq in a T-cell
lymphoma and identify novel transcripts that may have important functional roles in SS.
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Scaffold-Kinase interaction blockade selectively inhibits Ras-MAPK tumorigenesis
KL Jameson, A Zehnder and PA Khavari Stanford University, Stanford, CA
The Erk1/2 MAP kinase (MAPK) cascade is over-activated in ~30% of human cancers, often via
mutation of upstream RAS and RAF genes. The therapeutic impact of new inhibitors of mutant B-
Raf has been diminished by tumor resistance via selection for B-Raf-independent mechanisms of
Erk1/2 induction. Efforts to target endogenous MAPKs face the challenge that these kinases are
required for tissue viability in mammals. Scaffold proteins, such as IQGAP1, serve as nexuses in the
flow of cellular information by physically assembling signal transduction cascades and therefore
represent a mechanistic alternative to direct kinase targeting. An ideal scaffold target in cancer would
be required for tumorigenesis yet dispensable for homeostasis. Towards this goal, we observed that
IQGAP1 loss in epithelial tissue of mice and humans impaired Ras-driven tumorigenesis, but not
normal tissue homeostasis. Overexpression of the 32 amino acid WW domain of IQGAP1, which
is responsible for binding to Erk1/2, achieved similar effects, as did delivery of the WW peptide
itself. The WW domain sequence disrupted the IQGAP1-ERK1/2 interaction and attenuated Erk1/2
phosphorylation without disrupting normal tissue. Moreover, the WW peptide remained effective
against cells harboring activating BRAF mutations with acquired resistance to the B-Raf inhibitor
vemurafenib (PLX-4032), indicating that IQGAP1 WW domain-mediated scaffold-kinase interac-
tion blockade (SKIB) acts by a mechanism that is distinct from direct kinase inhibition. Targeting the
interaction between core oncogenic kinases and the scaffold protein that assemble them thus rep-
resents an alternative strategy to kinase inhibition in cancer.
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Detection of peripheral blood involvement in CTCL by multi-parametric flow cytometric
analysis
K Liu, KR Carlson, M Girardi and J Choi Dermatology, Yale School of Medicine, New Haven,
CT
Identification and quantification of circulating neoplastic cells in cutaneous T cell lymphoma is
important for early detection of disease as well as for monitoring tumor burden over time. Studies
have demonstrated that neoplastic T cells may lose expression of T cell markers CD7 and/or CD26,
and quantification using these phenotypes aids diagnosis and assessment of leukemic involvement.
In addition, detection of an expanded malignant clone in the peripheral blood is possible via anti-
bodies directed against the T cell receptor (TCR) β chain (anti-Vβ antibodies). We are performing a
prospective flow cytometric analysis to assess tumor burden in CTCL patients with blood involve-
ment. Blood from patients in our ECP clinic are longitudinally assessed for CD4/CD8 ratio, CD4+CD7-
and CD4+CD26- phenotype percentages and absolute number, and Vβ family percentages. Our ini-
tial observations suggest that a multi-parametric flow cytometric analysis may be used for a more
reliable and sensitive identification and quantitation of the neoplastic clone. In patients where the
neoplastic clones are less than 30%, the combination of markers can be used to identify a pro-
nounced clonal expansion expressing a specific TCR Vβ within a CTCL-specific subset, i.e. >90%
of the CD4+CD26- population. Furthermore, we found that in patients with an expansion of a
CD4+CD7- clone at diagnosis, the prevalence of these cells continue to approximate the preva-
lence of the neoplastic clone over time. Similar results are evident in patients with an expansion of
CD4+CD26- clones. These data suggest that the loss of CD7 or CD26 is a stable phenotype of the
leukemic CTCL cell, which may permit using these markers to track the tumor burden in response
to treatment. In summary, we propose that the use of such a multi-parametric analysis will be a reli-
able method to diagnose patients and to assess tumor burdens in cases that require standardization.
Longitudinally, the use of antibodies to CD7 and CD26 can be used to follow changes in tumor
burden over time.
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Dysregulation of the IL-1 family in cutaneous squamous cell carcinoma
A Aphale, X Xing, M Riblett, JE Gudjonsson and A Johnston Department of Dermatology,
University of Michigan, Ann Arbor, MI
Cutaneous squamous cell carcinoma (SCC) is a common malignancy of the skin. While keratinocyte
DNA damage plays a major role, alteration of immune responses is also thought to play a role in
its pathophysiology. IL-1α and IL-1β have both been implicated in SCC pathogenesis, but it is yet
unknown what role is played by other members of the IL-1 family, which includes 11 ligands and
9 receptors forming several distinct signaling systems. To address this we investigated differences in
the expression of these mediators between SCC and normal skin. QRT-PCR revealed up-regulation
of IL1A and IL1B in SCC 9.6-fold (p=0.001) and 10.5-fold (p=0.006) respectively, whereas IL1R1,
was down-regulated 2.4-fold (p= 0.001) and the IL-1 receptor antagonist, IL1RN, was up-regulated
2.2-fold (p=0.03). There were also differences in regards to the IL-18 and IL-36 members. IL37, which
is thought to be antagonistic to IL-18, was down-regulated 3.7-fold (p=0.02) in SCC; whereas expres-
sion of IL18 was unchanged. IL36A and IL36B were up-regulated in SCC, although this reached sig-
nificance only for IL36B whose levels were increased 8.8-fold (p=0.03); and the IL-36 antagonist,
IL36RN, was up-regulated 3.3-fold (p=0.0001). Interestingly, the ratio of IL36B to IL36RN was sig-
nificantly higher in SCC compared to normal skin (23.7-fold, p=0.01) suggestive of increased activ-
ity of the IL-36 system in SCC. Our QRT-PCR findings were supported immunohistochemically as
SCC tumor cells showed increased expression of IL-1α, IL-1β, IL-36β and the IL-36 antagonist IL-
36Ra with decreased expression of the IL-18 antagonist IL-37. Our findings indicate that there is a
complex dysregulation of the IL-1 family in SCC and this could play a role in the abnormal immune
response against tumor cells. These preliminary findings provide further insight into SCC biology
and may, in the future, help in development of more effective treatments.
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GLI2* engages the mTOR pathway to drive development of malignant peripheral nerve sheath
tumors (MPNSTs) in skin
AN Ermilov,1 E DeLassus,1 J Ferris,1 D Hong,1 J Pero,1 J Liu,1 M Grachtchouk,1 SJ Conway,2
DR Lucas3 and AA Dlugosz1 1 Dermatology, University of Michigan, Ann Arbor, MI, 2
Pediatrics, Indiana University, Indianapolis, IN and 3 Pathology, University of Michigan, Ann
Arbor, MI
MPNSTs are potentially lethal tumors that typically arise from plexiform neurofibromas in patients
with neurofibromatosis 1 (NF1). The NF1 gene encodes a Ras GTPase and its deficiency in tumors
leads to enhanced Ras activity. Unexpectedly, we discovered that mice with mosaic expression of
the Hedgehog pathway transcription factor GLI2* develop spindle cell sarcomas with a morphol-
ogy and marker profile that is characteristic of human MPNSTs. Given the proposed cell of origin
of these tumors, we generated mice carrying a Cre transgene expressed in Schwann cells (Postn-
Cre) and a Cre-inducible GLI2* allele (CLEG2). Postn-Cre;CLEG2 bitransgenic mice develop MPN-
STs with 100% penetrance by six weeks of age. Tumors arise in peripheral nerves, and both the his-
tology and immunophenotyping (S100β+, Nestin+) support a diagnosis of MPNST. To study the
timing of tumor initiation we generated doxycycline-inducible mice with GLI2* expression tar-
geted to the Schwann cell lineage. Typical MPNSTs arise with 100% penetrance in these mice, fre-
quently develop in skin of the snout, and are dependent on continued GLI2* expression for tumor
maintenance. We investigated signaling alterations in GLI2*-driven MPNSTs and identified robust
phosphorylation of the mTOR target S6. Moreover, treatment of GLI2*-expressing mice with the
mTOR inhibitor rapamycin impairs MPNST growth and extends survival, in keeping with results in
NF1-deficient MPNSTs which are also strictly dependent on mTOR signaling. Together, our data
reveal that GLI2* expression drives robust MPNST development by engaging the same oncogenic
downstream effector as NF1 loss, mTOR; establish that MPNSTs can arise in mature peripheral nerve
without a precursor lesion; identify the Schwann cell lineage as the source of MPNST tumor-initi-
ating cells in adult mice; and uncover a previously unrecognized link between GLI2* and the
mTOR/S6 signaling pathway in cancer.
178
Detection of non-melanoma skin cancer by in vivo fluorescence imaging with fluorocoxib
probe
H Ra,1,2 E Gonzalez-Gonzalez,1,2 M Uddin,4 I Ali-Khan,1,2 LJ Marnett,4 J Tang5 and CH Contag1,2,3
1 Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford,
CA, 2 Pediatrics, Stanford University School of Medicine, Stanford, CA, 3 Radiology and
Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, 4
Biochemistry, Chemistry, and Pharmacology, Vanderbilt University School of Medicine,
Nashville, TN and 5 Dermatology, Stanford University School of Medicine, Stanford, CA
Non-melanoma skin cancer (NMSC) is the most common form of cancer and the incidence is increas-
ing in the US. The current standard of care is visual inspection by a trained health care provider
and/or dermatologist, then pathologic confirmation via skin biopsy. We have investigated the use
of sensitive in vivo fluorescence imaging using fluorocoxib as a probe to detect and follow skin
tumors in mouse models of NMSC. Fluorocoxib targets the cyclooxygenase-2 (COX-2) enzyme that
is preferentially accumulated in inflamed and tumor tissue, and therefore has potential to be an
effective molecular probe for cancer detection. We tested the sensitivity of fluorocoxib in a BCC
allograft mouse model using a wide-field fluorescence imaging system with spectral unmixing. Sub-
cutaneously injected allografts comprised of 1000 BCC cells were detectable above background in
SCID hairless mice. These BCC allograft mice were imaged over time and a linear correlation (R2 =
0.8) between tumor volume and fluorocoxib signal levels was observed. We have also tested fluo-
rocoxib in a spontaneous BCC mouse model (Ptch1+/- K14Cre-ER2 p53fl/fl), where sequential imag-
ing of the same mice over time has shown that apparent microscopic (undetectable by visual inspec-
tion) early lesions (down to 100 μm size) developed into visible macroscopic tumor masses over
11-17 days. Histologic analyses of suspected microscopic tumors have shown 62% specificity (18/29)
and 91% sensitivity (40/44). These results demonstrate the potential of fluorocoxib as an in vivo
imaging agent for early detection and guided biopsies of NMSCs.
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Characterizing tumor adaptations via in vivo imaging
BJ Kubick and DR Roop University of Colorado Denver, Aurora, CO
Many decades of cancer research have led to a disappointing number of effective, long-lasting ther-
apies. This is in part due to the inherent ability of transformed cells to adapt to selective pressures.
The combination of high phenotypic heterogeneity and genomic instability makes cancer particu-
larly well-equipped to adapt to changing conditions. In the clinical setting, this manifests as recur-
rent disease following targeted therapies. For example, in hierarchically organized cancers, thera-
pies directed toward a particular phenotype may not actually affect all of the cells with tumorigenic
potential. While such treatments are able to debulk tumors, they are unable to completely eradi-
cate them. In fact, there is evidence that these incomplete treatments actually select for more aggres-
sive clones. Another type of selective pressure that obstructs tumor growth is presented by natural
tumor suppressive mechanisms of the surrounding microenvironment, ranging from hypoxic limi-
tation to antitumor immunity. These, natural barriers to cancer formation must be overcome by devel-
oping neoplasms in order to progress to malignancy. As with the treatment-resistant outgrowths
described above, cancer cells that surmount natural antitumor selection subsequently display a
selection-sculpted phenotype, often resulting in increased aggressiveness. In both cases, escaping
clones of cells provide the driving force behind persisting disease. Consequently, we are develop-
ing model systems that allow for characterization of escaping clones in both melanomas and non-
melanoma skin cancers (NMSCs) by coupling genetically initiated murine skin cancers to fluores-
cent labels. Using this technique, we are isolating and characterizing the population of cells within
a melanoma that survives debulking via MART-1 vaccination. We are also studying resistance to
intrinsic tumor suppressor mechanisms by similarly coupling a fluorescent label to an inducible
model of murine NMSC. Since this is a primary tumor model, we are able to follow, isolate, and
characterize cells as they adapt to overcome natural selective pressures such as immune surveil-
lance.
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